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SUMMARY
Despite extensive investigation, the effects of some aspects of
cardiopulmonary bypass upon haemodynamic and metabolic variables remain 
unresolved. Also, there have been great changes in the practice of
cardiopulmonary bypass over the years and the findings of early research may 
no longer be applicable to present day techniques. Three aspects of
cardiopulmonary bypass were identified as requiring investigation regarding their 
haemodynamic and metabolic effects: low flow  rates; flow  character ie
nonpulsatile or pulsatile perfusion; and acid-base management te pH or 
alpha-stat control.
Anaesthesia during cardiopulmonary bypass has been found in the past to 
have important metabolic effects which could be used to improve patient 
wellbeing and hence, outcome. However, these agents have been largely 
superseded by modern drugs that are metabolically untested. Although the 
effects on haemodynamic variables of most modern anaesthetics have been 
extensively studied before and after cardiopulmonary bypass, their actions 
during the abnormal conditions of cardiopulmonary bypass have not been 
rigorously examined.
It was hypothesised that cardiopulmonary bypass and anaesthetic 
techniques have important haemodynamic and metabolic effects. This thesis 
was undertaken to test this hypothesis.
In all the studies, arterial and mixed venous blood samples were analysed 
for oxygen content, saturation and tension, pH, carbon dioxide tension, base 
excess and lactate concentration. Systemic oxygen uptake and delivery were 
calculated.
Initially, a computerised system was developed to act as a data logger for 
haemodynamic, arterial pH and temperature measurements as well as to
9
Summary
enhance thermostatic and acid-base control. This system was tested and found 
to function well both as a recording device and as a means of obtaining good 
thermostatic control. However, the system performed poorly with regard to 
arterial pH control.
The haemodynamic and metabolic effects of flow  rate, flow  character and 
acid-base management during hypothermic cardiopulmonary bypass were 
studied in a factorial experiment. Of the three factors, only alternation of flow  
rate between 1.5 and 2 .0  L.min-1.m - 2 was found to have a significant effect on 
systemic oxygen uptake. Flow rate was also found to have a significant effect 
on mean arterial pressure and peripheral vascular resistance. Arterial pH and 
stage during cardiopulmonary bypass were found to significantly interact to 
influence mean arterial pressure but not peripheral vascular resistance. 
Alternation of flow  character between pulsatile and nonpulsatile perfusion had 
no significant effect on haemodynamic variables. Over and above these effects, 
a progressive vasoconstriction throughout cardiopulmonary bypass was noted.
Isoflurane’s effects on haemodynamic and metabolic variables were 
examined during hypothermic cardiopulmonary bypass. Isoflurane was found to 
be a vasodilator during these abnormal haemodynamic conditions although no 
systemic metabolic effects were identified.
Next, the haemodynamic and metabolic effects of atracurium during 
hypothermic cardiopulmonary bypass were studied. Neither haemodynamic nor 
metabolic effects were found from the use of atracurium.
Finally, the haemodynamic and metabolic effects of alfentanil and it’s 
antagonism with naloxone during hypothermic cardiopulmonary bypass were 
investigated. Neither alfentanil nor its antagonism with naloxone had any 
significant metabolic effect. However, administration of alfentanil prevented the 
expected increases in mean arterial pressure and peripheral vascular resistance 
that occur during the course of cardiopulmonary bypass. In contrast, antagonism 
of alfentanil with naloxone produced greater increases in mean arterial pressure
10
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and peripheral vascular resistance than would be predicted to occur simply as a 
result of stage.
Flow rate proved to be an important determinant of haemodynamics and 
metabolism during hypothermic cardiopulmonary bypass. This finding makes 
questionable the practice of reducing the pump flow  rate to low levels after 
induction of hypothermia. The lack of difference in haemodynamic and 
metabolic effects between nonpulsatile and pulsatile perfusion would add 
weight to the body of opinion which holds that flow  character has no important 
actions during clinical cardiopulmonary bypass. Arterial pH interacted with stage 
during cardiopulmonary bypass to influence mean arterial pressure. However, 
the clinical importance of this finding is uncertain as the size of effect was small. 
This haemodynamic finding and the lack of any difference in metabolic effect 
add no weight to the use of either alpha or pH-stat acid-base management.
The progressive vasoconstriction, found throughout these studies, is an 
important and well recognised phenomenon of cardiopulmonary bypass. The 
lack of any impairment in systemic oxygen uptake associated with this rise in 
peripheral vascular resistance contrasts strongly with the marked reduction in 
systemic oxygen uptake associated with the increase in peripheral vascular 
resistance that resulted from decreasing the flow rate. The metabolic effects 
associated with the increases in peripheral vascular resistance, either as a result 
of decreasing the flow  rate or due to vasoconstriction during the course of 
cardiopulmonary bypass, suggest passive and active mechanisms, respectively.
Isoflurane’s lack of metabolic effect contrasts with previous work in the 
intact cardiovascular system at normothermia. Possible explanations for this 
difference in findings are the use of hypothermia and a constant flow  rate. 
However, isoflurane proved to be a vasodilator which could be used to control 
hypertension during cardiopulmonary bypass whilst ensuring anaesthesia without 
the risk of awareness.
11
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The absence of any metabolic action with the use of atracurium is in 
contrast to tubocurarine which has previously been been found to reduce 
systemic oxygen uptake. The use of hypothermia in the present study and the 
fact that atracurium, unlike tubocurarine, has minimal haemodynamic effects may 
account for the differing findings.
A lfentanil’s lack of metabolic effect may have been predictable as opioids 
only have metabolic actions in a few specialised circumstances. However, the 
haemodynamic effects of alfentanil were unexpected considering its minimal 
actions in the intact cardiovascular system at normothermia. The present 
findings indicate that opioids, such as alfentanil, play an important role in 
ameliorating the vasoconstriction that is ongoing throughout cardiopulmonary 
bypass.
In conclusion, the hypothesis that cardiopulmonary bypass technique has 
important haemodynamic and metabolic effects was proved true only with 
respect to flow  rate. With regard to anaesthesia, the hypothesis held true for 
haemodynamic effects but could not be supported for metabolic actions.
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CHAPTER 1 
INTRODUCTION
Cardiopulmonary bypass is the keystone that presently enables cardiac 
surgery to be undertaken on hundreds of thousands of patients every year. In a 
remarkably short time, cardiopulmonary bypass has become a routine clinical 
technique as it was only in 1937 that Gibbon first proposed the use of 
cardiopulmonary bypass to enable surgeons to operate on intracardiac 
abnormalities under direct vision 1. What was pioneering work just over four 
decades ago is now an everyday occurrence in most major hospitals around the 
world.
The purpose of cardiopulmonary bypass is to allow the normal function of 
the heart and lungs to be suspended whilst surgery on these vital structures is 
perform ed. This function is achieved m echanically by supplying 
oxygenated blood to the tissue in sufficient quantity to allow continued aerobic 
metabolism. Basically, cardiopulmonary bypass involves syphoning blood from 
the patient’s venous system into a reservoir, where carbon dioxide is removed 
and oxygen added to the blood before it is pumped back into the patient’s 
arterial system. However, this activity requires major physiological trespass with 
considerable risk to the patient. At the outset, a high mortality and morbidity 
were implicit in cardiopulmonary bypass 2. When balanced against the potential 
to remedy life threatening and previously untreatable cardiac disease, the risks 
of cardiopulmonary bypass were considered acceptable. Today, the mortality for 
all types of surgery involving cardiopulmonary bypass in the United Kingdom is 
8.5% and for coronary artery surgery alone, it is only 3.2% 3. Because of the 
present relatively low risk from cardiopulmonary bypass, the focus of cardiac 
surgery has moved from the correction of life threatening cardiac conditions, 
such as congenital and valvular heart diseases, to the mostly symptomatic 
treatment of coronary artery disease.
13
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Undoubtedly, the present low risk of surgery involving cardiopulmonary 
bypass stems from much fundamental research during the pioneering years to 
establish a modus operandi as well as from technical advances in equ ipm ent2. 
Although patient outcome will always be the final criteria, systemic 
haemodynamic and metabolic variables have been employed from the 
beginning as sensitive measures of the adequacy of cardiopulmonary bypass 
and to date, they remain important indices.
Early subjects for investigation of cardiopulmonary bypass were the 
haemodynamic and metabolic effects of flow  rate, hypothermia and pulsatile 
perfusion 4~8. Despite continued study, the haemodynamic and metabolic effects 
of some basic cardiopulmonary bypass techniques, for example low flow  rates 
9'10, pulsatile perfusion 1112 and acid-base management 13-15, have remained 
largely unresolved. Moreover, there have been great changes in the practice of 
cardiopulmonary bypass over the last forty years, for example hypothermia and 
haemodilution are both now standard in most centres. Extrapolation from early 
findings to modern practice may therefore be no longer appropriate.
The actions of anaesthetic drugs before and after cardiopulmonary bypass 
have been extensively studied 1617. In contrast, their actions during 
cardiopulmonary bypass have been largely ignored. Anaesthesia for cardiac 
surgery has changed out of all recognition over the last four decades and this is, 
at least in part, because of the introduction of modern anaesthetic drugs. The 
metabolic and haemodynamic effects of only a few  anaesthetic agents have 
ever been studied during cardiopulmonary bypass and virtually none of the 
modern anaesthetic drugs have been investigated. Yet anaesthetic agents are 
known to have important haemodynamic and metabolic effects which cuuid be 
used to advantage during cardiopulmonary bypass to improve still further the 
outcome from cardiac surgery 18.
Modern cardiac anaesthesia in the United Kingdom, with the notable 
exception of high dose opioid techniques, is based on Lundy’s concept of
14
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balanced anaesthesia 19. By using a combination of specific agents in small 
amounts to produce the triad of anaesthesia that is analgesia, hypnosis and 
muscle relaxation, the adverse effects of anaesthesia are minimised compared 
to employing a high dose of a single agent to produce all three components. A 
vast array of drugs are used to produce this triad for cardiac anaesthesia though 
they can be classified into four groups which are; opioids, neuromuscular 
blockers, intravenous and inhalational anaesthetic agents 20. Opioids and 
neuromuscular blocking drugs are almost universally employed to produce 
analgesia and muscle relaxation respectively whereas either inhalational or 
intravenous anaesthetic agents are used for hypnosis. Because of the large 
number of drugs that are presently used for cardiac anaesthesia, Lundy’s triad 
makes a suitable basis upon which to study the effects of anaesthesia on 
haemodynamic and metabolic variables during cardiopulmonary bypass.
In conclusion, the purpose of this thesis is to re-evaluate the effects of 
certain unresolved aspects of cardiopulmonary bypass technique on 
haemodynamic and metabolic variables in the light of present day anaesthetic 
and cardiopulmonary bypass practice. It w ill then examine the effects of 
balanced anaesthesia during cardiopulmonary bypass upon these variables. 
Ultimately, it is hoped to determine the most efficacious combination of 
cardiopulmonary bypass and anaesthetic techniques in terms of the 
haemodynamic and metabolic wellbeing of the patient during cardiopulmonary 
bypass.
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CHAPTER 2 
HISTORICAL REVIEW
In order to establish the background to this thesis, this chapter will review 
the methods that have been used to measure systemic haemodynamics and 
metabolism during cardiopulmonary bypass and how different techniques of 
cardiopulmonary bypass affect these variables. Anaesthesia’s effect upon these 
variables during cardiopulmonary bypass will then be considered.
Cardiopulmonary bypass has important actions on many systems other 
than haemodynamics and metabolism. For example, it can cause severe 
coagulopathy and cerebral dysfunction. Also, there have been major advances 
in equipment design over the years, such as the development of roller pumps, 
which have contributed greatly to  the present improved safety of 
cardiopulmonary bypass. As they have been extensively examined previously 
21~24, these aspects of cardiopulmonary bypass will not be considered further in 
this review which will concentrate first, on systemic metabolism and then, 
systemic haemodynamics during cardiopulmonary bypass.
METABOLISM
The German physiologist, Pfluger, was the first to realise that the primary 
functions of the cardiopulmonary system were to guarantee cellular oxygen 
supply and to remove waste products of metabolism. Pfluger stated that all else 
was secondary:
“ Arterial oxygen content, arterial pressures, blood flow 
velocity, mode of cardiac work and mode of respiration, all 
are incidental and subordinate; they all combine their 
actions only in service to the cells.' 2b
16
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This concept remains totally applicable to the function of cardiopulmonary 
bypass today. The bulk of oxygen consumed by the cells is used in the release 
of energy from foodstuffs by oxidative phosphorylation in the mitochondria 
although a considerable fraction of it is required for other enzymatic functions. 
Cone and Dennison have both recently reviewed in detail the cellular usage of 
oxygen and so, it will not be considered further here 2627. This review will 
instead consider the measures of systemic metabolism that have been used to 
assess the adequacy of cardiopulmonary bypass.
MEASURES OF METABOLISM
Systemic oxygen uptake
As the essential function of cardiopulmonary bypass is to supply 
oxygenated blood to the tissues in quantities sufficient to allow continued 
aerobic metabolism, systemic oxygen uptake is the prime metabolic measure of 
the adequacy of cardiopulmonary bypass. Systemic oxygen uptake is 
determined by the balance between oxygen delivery and tissue oxygen 
demands. If the delivery of oxygen is adequate then systemic oxygen uptake is 
dependent on metabolic rate. Should oxygen delivery become inadequate, 
systemic oxygen uptake is limited as there are little or no tissue stores of 
oxygen. Continued metabolism beyond this point becomes anaerobic; lactic 
acid is produced and metabolic acidosis results. For these reasons, systemic 
oxygen uptake has long been established as an important measure of the 
performance of cardiopulmonary bypass 4~7.
In the intact cardiovascular system, systemic oxygen uptake can be 
measured by direct or indirect methods 2&. The direct method involves analysing 
the composition of gases inspired and expired from the lungs over a known 
period of time. As the lungs are excluded from the circulation and gases are
17
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exchanged by the oxygenator, this method is not applicable during 
cardiopulmonary bypass. Theoretically, systemic oxygen uptake could be 
ascertained directly by measurement of the composition and volume of gases 
supplied to and exhausted from the oxygenator over a known time, but this 
method has not been validated. The simpler and established method ot 
determining systemic oxygen uptake during cardiopulmonary bypass is 
indirectly, using Fick’s principle 29. Although Fick originally proposed his method 
as a means of determining cardiac output in the intact cardiovascular system, 
simple substitution of the formula allows determination of systemic oxygen 
uptake during cardiopulmonary bypass using the product of the arterio-venous 
oxygen content difference and pump flow  rate.
Carbon dioxide production
Carbon dioxide is the major end product of metabolism. Therefore, for 
similar reasons to systemic oxygen uptake, carbon dioxide output could also be 
used to measure systemic metabolism and so, the adequacy of cardiopulmonary 
bypass. However, carbon dioxide is often added to the oxygenator in variable 
amounts to control the acid-base balance and this unquantifiable factor would 
confound the reliability of any measurements of carbon dioxide production.
Systemic oxygen delivery
As low levels of oxygen supply can limit systemic oxygen uptake and 
result in anaerobic metabolism, systemic oxygen delivery is an important 
metabolic indice during cardiopulmonary bypass. Oxygen delivery to the tissues 
is dependent on the product of flow  rate and arterial oxygen content. Pump 
flow  rate is generally set at pre-determined levels during cardiopulmonary 
bypass. If hypothermia is used in conjunction with cardiopulmonary bypass, 
flow  rate is often reduced to low levels so restricting systemic oxygen delivery 
and this important aspect will discussed in detail later. If flow  rate is fixed, then 
arterial blood oxygen content becomes the critical measure that determines 
systemic oxygen delivery.
18
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Arterial oxygen variables
Arterial hypoxaemia can limit systemic oxygen uptake 30 and therefore, it’s 
prevention is important during cardiopulmonary bypass. The oxygen content of 
arterial blood is related to the haemoglobin concentration and the saturation of 
haemoglobin with oxygen plus the amount of oxygen dissolved in plasma which 
is dependent on the oxygen tension 28. Although it can be determined indirectly 
using these variables, blood oxygen content is more accurately measured 
directly 31.
Venous oxygen variables
Mixed venous blood oxygen content, saturation and tension have all been 
widely advocated as indices of systemic metabolism during cardiopulmonary 
bypass 32 39, the assumption being that they reflect the average state of tissue 
oxygenation. Mixed venous oxygen tension has been advanced by Stanley and 
Isern-Amaral as being more sensitive than saturation in predicting perfusion 
requirements and so, allowing earlier detection of imbalance between oxygen 
supply and demand 38. However, interpretation of these variables can be very 
difficult as they may be confounded by a variety of unquantifiable factors and 
capillary shunting is an excellent example of this problem. As a result, it is 
unclear whether low or high values of mixed venous blood content, saturation or 
tension indicate adequate perfusion 22'40.
Lactic acid
When systemic oxygen delivery decreases, oxygen extraction by the 
tissues increases to maintain a normal systemic oxygen uptake. Should 
systemic oxygen delivery fall below a critical level that is associated w ith near 
maximal oxygen extraction, then cells must resort to anaerobic biochemical 
pathways for vital energy production 4142. At this point oxygen uptake becomes 
supply dependent. Lactic acid, being the end product of anaerobic metabolism, 
accumulates intracellularly and is then released into the blood. For this reason 
lactate concentration has been widely used as an index of the adequacy of
19
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cardiopulmonary bypass 5.43-48 Ear|y studies found that lactic acid concentration 
progressively increased over the course of cardiopulmonary bypass 5 48. In 
severe cases, there was lactic acidosis and this was associated with a high 
mortality 5. However, the value of monitoring lactate concentration during low 
flow  cardiopulmonary bypass has been questioned by Harris, Seelye and 
Barratt-Boyes as they found that important changes in systemic oxygen uptake 
occured without concommitant alteration in lactate concentration 48.
Base excess
If anaerobic metabolism occurs, the increase in fixed acids will result in 
metabolic acidosis with a decrease in plasma bicarbonate. In the past, arterial 
pH has been used as a measure of the adequacy of perfusion during 
cardiopulmonary bypass and a progressive acidosis was a frequent finding 4534. 
Marked acidosis was associated with a high mortality 5. However, as pH is 
mainly controlled and readily adjusted during cardiopulmonary bypass by the 
respiratory component of acid-base balance (the amount of dissolved carbon 
dioxide), base deficit rather than pH is now used as an index of acid-base 
balance and so, of anaerobic metabolism 6.36.43
Invasive measurements
All the above variables are indices of the adequacy of systemic perfusion. 
However, they may not represent the adequacy of perfusion in all tissues. For 
this reason, Pranger and colleagues have used tissue P 0 2 histograms and they 
have detected changes in shape of the histograms to occur before changes in 
any systemic variables 49. However, as it is uncertain which tissues should be 
monitored and because of it’s invasive nature, tissue P 0 2 histograms will not be 
used here.
20
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EFFECTS OF CARDIOPULMONARY BYPASS ON METABOLISM
Cardiopulmonary bypass includes many factors that may influence 
metabolism. This section will review the metabolic effects of these factors and 
identify those which remain unresolved. The effect of anaesthesia during 
cardiopulmonary bypass on metabolic variables will then be considered.
Flypothermia
Although a few  centres still use normothermia, the majority employ some 
degree of hypothermia in conjunction with cardiopulmonary bypass. By reducing 
the rate of biochemical reactions, hypothermia causes a marked decrease in 
systemic oxygen uptake. The quantitative inter-relationships between these 
factors have been described mathematically in various ways 22. Some, such as 
Ross 50, have used a linear model. Others, including Harris Seelye and Squire 51, 
have used a model based on Arrhenius’s theory, which states that the logarithm 
of a chemical reaction is inversely proportional to the reciprocal of the absolute 
temperature. A sigmoid curve represents this relationship such that at very high 
temperatures the reaction rate ceases to increase with temperature. However, 
at physiological temperatures, biochemical systems operate only on the 
upswing of the curve. This relationship, especially if the temperature range is 
small, is expressed by van’t H off’s law which relates the logarithm of the 
chemical reaction directly to temperature. According to this equation, the 
reaction rate increases by tw o to three times for each 1 0°C rise in temperature 
and this ratio is called the Q10. Studies of tissue slices confirm this relationship 22 
although, in humans, the Q 10 is variable and dependent on the tim ing of 
hypothermia 2251. However, this discrepancy in humans may be explained by 
uneven cooling of the body 52.
The reduction in metabolism induced by hypothermia is used to advantage 
during cardiopulmonary bypass as tissue ischaemia or hypoperfusion can be 
tolerated for a longer time, before irreversible functional or structural damage
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occurs, than would be the case at normothermia. Originally, hypothermia was 
clumsily achieved by immersion in iced water or external application of ice 
packs 22. Today, hypothermia and rewarming are easily obtained by using heat 
exchangers incoroorated into the oxvnenato r22 Thus, hypothermia is a valuable 
and easily spread safety net in the event of perfusion mishap or inadequate 
perfusion.
As well as systemic benefits, hypothermia also has advantages for 
myocardial protection. Even during aortic cross clamping, systemic blood may 
enter the heart via non-coronary collateral vessels and rewarm the heart. 
Therefore, using low body temperatures helps to slow rewarming and provide 
myocardial protection. Kirklin and Barratt-Boyes 54 have reviewed this aspect of 
systemic hypothermia and so, it will not be considered further here.
Hypothermia may also have an adverse metabolic effect as it causes a 
leftward shift of the oxygen haemoglobin dissociation curve. This leftward shift 
results from an increased affinity of oxygen to haemoglobin and may limit the 
availability of oxygen to the tissues 3654. However, a local decrease in pH, an 
increase in local carbon dioxide tension and an increase in 2,3- 
diphosphoglycerate will shift the curve to the right and counteract this 
undesirable effect of hypothermia 55.
Although hypothermia is generally agreed to be valuable, there is 
widespread disagreement as to the optimum degree of hypothermia. Mild 
hypothermia (29-35°C) is used by some centres whilst others employ profound 
hypothermia (<25°C). Although there are metabolic advantages with more 
profound degrees of hypothermia there are also practical disadvantages. When 
profound degrees of hypothermia are used, longer is required to cool and, 
subsequently, to rewarm the patient back to normothermia. During cooling, and 
more especially rewarming, the patient is vulnerable to hypoperfusion and 
therefore, it is best to spend the minimum possible amount of time in these 
phases. Moreover, cardiovascular instability and shivering, which is associated
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with an increased systemic oxygen uptake, can result during the crucial 
postoperative period due to an afterdrop in body temperature. The more 
profound the degree of hypothermia used then the greater the like lihood that 
there will be a serious afterdrop in body temperature. For these reasons, many 
centres compromise by using moderate hypothermia (25-28°C) 22 as will the 
presented series of studies.
Haemodilution
Originally cardiopulmonary bypass circuits were primed only with blood. In 
the desire to conserve blood, haemodilution with crystalloid or colloid solutions 
was introduced and is now widely employed 5657. However, haemodilution 
decreases the oxygen carrying capacity of the blood which can limit systemic 
oxygen delivery. Nonetheless, systemic oxygen uptake is maintained during 
haemodilution in animal experiments until the haematocrit falls below 20%, at 
which point it becomes directly proportional to the haematocrit 58. Furthermore, 
Roe and colleagues found that metabolic acidosis was remarkably absent when 
a clear priming solution was employed 59.
Flow rate
Pump flow  rate is an important determinant of systemic oxygen uptake 
during low flow  cardiopulmonary bypass 22. At low levels of flow , systemic 
oxygen uptake is directly related to pump flow  rate. As flow  rate increases, a 
point is reached where systemic oxygen uptake becomes independent of flow  
and plateaus out (Figure 1). Maintenance of flow  rate at or above this point 
would be the optimum as lower rates will result in metabolic acidosis 5.
Although the general relationship between flow  rate and systemic oxygen 
uptake is agreed, the actual flow  rate at which systemic oxygen uptake plateaus 
remains disputed. Rates varying from 1.2 to 2.0 L.min-1.m-2 and even higher 
have been proposed 4-7,40,60-62. Because such wide differences exist in the 
control of body temperature in previous studies, ranging from normothermia to
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profound hypothermia, it is difficult to make a valid overall comparison of them. 
Even studies which have used similar degrees of hypothermia have produced 
conflicting results 4061. Some of the previous work can also be criticised for their 
choice of experimental design and statistical analysis. Hickey and Hoar, who 
concluded that systemic oxygen uptake plateaued at 1.2 L.min-1.rrr2 during 
moderate hypothermia 6'*, used a fixed order of investigation and did not control 
for stage during cardiopulmonary bypass. Fox and co-workers, using profound 
hypothermia, did control for stage of investigation and also concluded that 
systemic oxygen uptake plateaued at 1.2 L.min-1.m-2 6f. This conclusion was 
made despite their results apparently showing increases in systemic oxygen 
uptake at higher flow rates. A decision to analyse data as individual points, 
rather than examine within patient changes, may account for their finding as this 
will have resulted in a marked loss of sensitivity.
The importance of the relationship between systemic oxygen uptake and 
flow  rate lies in the frequent use of low levels of flow  during hypothermic 
cardiopulmonary bypass. During cooling and rewarming, relatively high flows of 
about 2.4 L.min-1.m-2 are commonly used 2263. However, flow  rates are often 
cut back to between 1 and 2 L.min-1.m-2 after induction of hypothermia and 
some centres even use flow  rates as low as 0.25 L . m i n V m 2 for short 
periods 60. The main reason for using low flow  rates is to reduce non-coronary 
collateral blood flow and thereby, improve myocardial preservation 5364. 
Increased risk of gaseous microemboli, decreased bleeding into the surgical 
field and reduced haemolysis are other important reasons for using low rates of 
flow  22. Underpinning this manipulation of flow  rate is the physiological rationale 
that sufficient oxygen will still be delivered to the tissues to maintain systemic 
oxygen uptake, despite the low flow  rate, because of the reduced metabolic 
rate induced by hypothermia 22,60,61 However, if this premise does not hold true 
then large numbers of patients are experiencing sub-optimal levels of oxygen 
uptake.
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Although a few centres may use flow  rates around 1.2 L.min-1.m-2 during 
moderate hypothermia, the greater majority normally employ rates between 1.5 
and 2.0 L.min-1min-2. For this reason, it is important to determine whether or not 
systemic oxygen uptake is flow  dependent at the low levels of flow  rate 
commonly used during hypothermic cardiopulmonary bypass.
Flow character
Many of the early cardiopulmonary bypass pumps were designed to 
reproduce the natural pulsating character of blood flow  generated by the heart. 
However, the complexity of these systems proved to be an insurmountable 
barrier to their continued use 65. Roller pumps, which produced continuous or 
nonpulsatile perfusion, proved to be reliable and safe. This, along w ith the lack 
of conclusive evidence that pulsatile perfusion had any benefits, over 
nonpulsatile perfusion, resulted in roller pumps becoming the standard by the 
end of the 1960s 2365. However, evidence began to accumulate that nonpulsatile 
flow  was detrimental to cellular metabolism and organ function 65. As a result, 
modified roller pumps that can produce a pulsatile flow  character were 
developed and have been commercially available for some years now. These 
have been demonstrated to be safe, reliable and simple to operate in routine 
clinical use 65. No technical barrier now exists to the use of pulsatile perfusion 
but whether there are metabolic advantages to the use of pulsatile over 
nonpulsatile flow  character remains unsettled 12.65.66
Pulsatile perfusion is advocated by Taylor, amongst other reasons, as 
being metabolically superior to nonpulsatile perfusion 65. This recommendation 
is based on a number of studies that have found pulsatile perfusion to increase 
systemic oxygen untrue anri imnmwp nthor indices of metabolism rnmnarpd m 
nonpulsatile perfusion 43-45,67-70 c lose  examination of several of these studies 
reveals them to be statistically unsound as flow rates were higher in pulsatile 
than nonpulsatile groups 45,67,68 a s discussed previously, systemic oxygen 
uptake is inversely related to flow  rate at low levels of flow. Therefore, any 
increases in the pulsatile, compared to the nonpulsatile groups, may be related
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to the differences in flow  rate rather than any differences in flow  character. Also, 
most studies of flow  character have employed an unpaired, parallel group 
design which raises serious problems of matching when comparing a size 
dependent variable such as systemic oxygen uptake 47. Furthermore, several 
animal and human studies have been unable to demonstrate any metabolic 
superiority of pulsatile over nonpulsatile perfusion *7.71,72. These differences in 
findings have been reconciled by Hickey, Buckley and Philbin 12 on the basis that 
those studies, which failed to find that pulsatile perfusion had any advantages 
over nonpulsatile, employed high flow  rates (>100 m l.min-1.kg) and that the 
difference between flow  characters only become apparent when low flow  rates 
(60-100 m l.min-1.kg) are used.
Another serious criticism raised by Hickey, Buckley and Philbin 12 of many 
previous studies is the failure to quantify the pulsatile nature of the flow  
produced. This fact, along with the great variety of devices used to create 
pulsatile perfusion, makes comparison of previous findings extremely difficult. 
Thus, if any differences in metabolic effects exist between nonpulsatile and 
pulsatile perfusion, particularly during low flow  cardiopulmonary bypass, they 
remain unclear.
Acid-base management
Conventionally, the aim of acid-base management was to maintain 
homeostasis by guarding the arterial pH around 7.4 and this concept was 
perpetuated into routine cardiopulmonary bypass practice 73. Under this pH-stat 
theory of acid-base management, arterial pH is maintained at 7.4 when the 
blood sample is measured by bench blood gas at 37°C and the results 
interpreted follow ing correction for body temperature 73. From the introduction 
of hypothermia until the present day, this concept has been disputed 13 , 14 , 7 3 -7 6  
Some authors have advocated that acidosis should be induced with the addition 
of carbon dioxide or even hydrochloric acid 75. Others have favoured alkalosis 
4876 and in recent years, support for this view has been given by the work of
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Rahn and Reeves and Howell and colleagues on the grounds of stability of the 
hydroxyl/hydrogen ion ratio and maintenance of a constant net charge of 
imidazole 77~79. This alpha-stat theory of acid-base management allows the 
arterial pH to rise with decreasing temperature as would occur in a closed 
system 80. Alpha-stat control is achieved by maintaining the arterial pH at 7.4 
when the results, measured by bench blood gas analysis at 37°C, are 
interpreted without correction for body temperature 73.
It has been estimated that over 50% of centres for cardiac surgery now 
employ alpha-stat acid-base management 74. Blayo and colleagues have 
applied alpha-stat acid-base management in humans and found normal levels 
of systemic oxygen uptake 81. However, Harken demonstrated a significant 
correlation between arterial pH and oxygen uptake using a canine hind limb 
model 82. Human research, performed at or near normothermia, has produced 
conflicting results as Springer and co-workers found systemic oxygen uptake to 
diminish with increases in arterial carbon dioxide 83 whereas Patterson found the 
opposite 84.
At present, there is insufficient data available on the effects of acid-base 
management on systemic metabolism during hypothermic cardiopulmonary 
bypass in humans.
Having considered how metabolic variables are affected by the different 
factors of cardiopulmonary bypass, this review will now concentrate on how 
they are influenced by anaesthesia during cardiopulmonary bypass.
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EFFECTS OF ANAESTHESIA DURING CARDIOPULMONARY BYPASS
ON METABOLISM
Remarkably few studies of anaesthesia’s effects upon metabolic variables 
during cardiopulmonary bypass have been undertaken despite the early work of 
Underwood, Roth and Starr 85 which demonstrated that the choice of 
anaesthesia affected systemic oxygen uptake. However, most anaesthetic 
agents used at the time of their work have fallen into disuse as they have been 
superseded by modern drugs. The effects on metabolic variables during 
cardiopulmonary bypass of these modern anaesthetic drugs have not been 
tested. If the findings of Underwood, Roth and Starr 85 hold true with present 
day anaesthetic agents, then the choice of anaesthesia during cardiopulmonary 
bypass may have important actions on systemic metabolism and may, in turn, 
influence outcome from cardiac surgery.
Anaesthesia has two potential means of benefitting patients metabolically 
during cardiopulmonary bypass. Direct metabolic depression by anaesthetic 
agents may, like hypothermia, have a systemic protective action thus allowing 
ischaemia or hypoperfusion to be tolerated longer before structural damage 
occurs. Alternatively, some anaesthetics are potent vasodilators. This 
vasodilation could be used to advantage by increasing perfusion within areas of 
excessive vasoconstriction and thereby improving metabolism.
Presently, a tremendous variety of techniques are used by anaesthetists in 
the United Kingdom and Ireland to produce anaesthesia during cardiopulmonary 
bypass 20. Although diverse in their constituents, these techniques are, with the 
notable exception of opioid anaesthesia, based on Lundy’s principle of balanced 
anaesthesia 19. Balanced anaesthesia uses a combination of agents to produce 
the classic triad of analgesia, anaesthesia and muscle relaxation 19. Although a 
great variety of drugs are used to produce this triad, they can be classified into 
four groups which are opioids, neuromuscular blocking agents, inhalational and
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intravenous anaesthetics. Opioids are used for analgesia; neuromuscular 
blocking agents for muscle relaxation; and either inhalational or intravenous 
anaesthetics can be used for hypnosis. The effects of anaesthesia during 
cardiopulmonary bypass will be considered on the basis of this grouping.
Cardiopulmonary bypass has important effects on the pharmacokinetics of 
anaesthetic drugs which are beyond the scope of this thesis. These actions have 
been reviewed previously 18 and will therefore not be considered further in this 
review which will now concentrate on the metabolic effects of each separate 
anaesthetic group.
Inhalational anaesthetics
Since the early days of cardiopulmonary bypass inhalational anaesthetic 
agents have been used during cardiopulmonary bypass and they are still 
frequently employed 20.85.86 inhalational anaesthetic agents, by definition, are 
usually administered via the lungs. However, exclusion of the lungs from the 
circulation during the larger part cardiopulmonary bypass makes inhalation an 
impracticable method of delivery. In this situation, they can be administered 
simply by vaporising the agents into the gas supply to the oxygenator and 
halothane has long been employed in such a manner 86.
Halothane is known to reduce systemic oxygen uptake in the intact 
cardiovascular system at normothermia 87. Its effect on systemic oxygen uptake 
during hypothermic cardiopulmonary bypass has not been studied, although 
Norden found that the use of halothane prevented the base excess from 
decreasing 88. Because of its potential to cause hepatitis in a small number of 
patients on repeated exposure 89, halothane is falling into disuse and is now 
infrequently used during cardiopulmonary bypass 20. Isoflurane also decreases 
systemic oxygen uptake in the intact cardiovascular system at normothermia 
9°-92 and therefore, it may have a systemic protective effect during 
cardiopulmonary bypass. As discussed later, isoflurane has a vasodilatory action 
which may reduce the relatively elevated peripheral vascular resistance that
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exists during low flow , hypothermic cardiopulmonary bypass. If this is so, 
improved perfusion in areas of ischaemia or hypoperfusion will result in an 
increase in systemic oxygen uptake. However, the metabolic effects of 
isoflurane rlurinn cardionulmonary bypass have not been previously studied
Neuromuscular blocking agents
Neuromuscular blocking agents are almost invariably employed to produce 
muscle relaxation during cardiac anaesthesia 20. Systemic oxygen uptake has 
been found by Underwood, Roth and Starr to be lower in patients during 
normothermic cardiopulmonary bypass if an anaesthetic technique involving a 
neuromuscular blocking agent (decamethonium or tubocurarine) is used 
compared to one employing cyclopropane alone 85. A decrease, from 
preoperative values, in systemic oxygen uptake has also been found during 
normothermic cardiopulmonary bypass by Harris, Seelye and Squire 51 who 
attributed the decrease to the administration of the tubocurarine. The findings of 
these two studies would indicate that neuromuscular blocking agents have a 
systemic protective effect during cardiopulmonary bypass similar to that of 
hypothermia.
Decamethonium is no longer used clinically as a neuromuscular blocking 
agent. Tubocurarine, as discussed later, can result in de-stabilisation of the 
cardiovascular system and therefore, is infrequently used now for cardiac 
anaesthesia 20. Atracurium and vecuronium are two modern neuromuscular 
blocking agents which have similar actions to each other. For haemodynamic 
reasons which are discussed later, they are now commonly used during cardiac 
anaesthesia 93 94. However, the effects on metabolic variables of these 
neuromuscular blocking agents during cardiopulmonary bypass have not been 
investigated.
Opioids
Opioids are nearly always used to produce the analgesic component of 
balanced anaesthesia during cardiopulmonary bypass 20 95. Morphine was
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formerly the standard opioid for cardiac anaesthesia but it has been superseded, 
for reasons discussed later, by synthetic opioids such as fentanyl and 
alfentanil 95.
No direct evidence exists to suggest that opioids have any metabolic 
effect during cardiopulmonary bypass. However, antagonism of opioids in 
animals and humans can result in marked increases in systemic oxygen uptake 
which might imply that opioids could have important metabolic effects during 
cardiopulmonary bypass 96 97. Yet none of the modern opioids that are used for 
cardiac anaesthesia have been tested for their metabolic effects during 
cardiopulmonary bypass.
Some workers even employ opioids in high doses as the sole agent to 
produce anaesthesia 95. This technique has been advocated because it produces 
good cardiovascular stability 95. However, the reliability of opioids on their own 
to produce anaesthesia is open to question 9598. For this reason, opioids are 
usually supplemented with a volatile or intravenous anaesthetic agent to obtain 
hypnosis 20.
Intravenous anaesthetics
Intravenous anaesthetics are a large and disparate group of drugs that are 
often used, as an alternative to inhalational anaesthetics, to produce the 
hypnosis component of balanced anaesthesia during cardiopulmonary bypass 20. 
Of these agents, chlorpromazine is the only one that has been investigated for 
its effects on systemic oxygen uptake during cardiopulmonary bypass. Arikawa 
and colleagues found that chlorpromazine increased systemic oxygen uptake 
when patients were cooled below 32°C 99. However, their use of simple 
regression analysis makes their conclusions questionable. Also, chlorpromazine 
is now rarely used during cardiac anaesthesia 20. This declined usage is probably 
because of chlorpromazine’s cardiovascular side effects which are discussed 
later. A large variety of other types of intravenous anaesthetic agents such as 
barbiturates, benzodiazepines and other unrelated drugs are used 20 but their
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systemic metabolic effects during cardiopulmonary bypass have not been 
investigated.
As there is no single intravenous anaesthetic that is representative of the 
group and because of the great number of different types of drugs that can be 
classified as intravenous anaesthetics, this thesis will not attempt the exhaustive 
process that would be required to determine the metabolic effects of this group 
of drugs. However, this omission should not belittle the importance of this 
group of drugs as anaesthetic agents during cardiopulmonary bypass.
Having considered the effects of the different aspects of cardiopulmonary 
bypass and the effects of anaesthesia during cardiopulmonary bypass on 
metabolic varaibles, this review will move on to deliberate on the 
haemodynamic aspects of cardiopulmonary bypass.
HAEMO DYNAMICS
Cardiopulmonary bypass is unique in clinical practice because it allows 
study of the vascular system in isolation from the heart. However, 
cardiopulmonary bypass causes major haemodynamic derangement and 
moreover, this derangement is a dynamic one. Following an initial marked 
decrease in peripheral vascular resistance with hypotension, there is a 
progressive vasoconstriction which continues into the postoperative period and 
can result in hypertension.
The initial drop in peripheral vascular resistance was originally attributed to 
inadennate nerfusion 100 However, this decrease occur? oven if the nnmn flow  
rate is set at or even higher than the patients own cardiac output 10°. Other 
theories that have been proposed and discredited are that it is due to a shock 
like state, dilution of vasoactive substances, inundation of the vascular system 
with cold priming solution or as a reaction to blood prime 100-102. However, it is
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now accepted that haemodilution is responsible as it has been demonstrated to 
cause a sudden profound drop in peripheral vascular resistance by reducing the 
blood viscosity 100.103
Following the initial hypotensive phase, there is a progressive rise in 
peripheral vascular resistance and arterial pressure 10°. A variety of mechanisms, 
both humoral and neural, have been proposed for this vasoconstriction. 
Catecholamines, vasopressin and thromboxanes have all been implicated as 
mediators of this vasoconstriction as have increases in sympathetic tone and 
the use of nonpulsatile perfusion 12 .6 5 1 0 4 -11 0  j h e ongoing vasoconstriction 
continues into the post-cardiopulmonary bypass period and has important 
implications for mycocardial oxygen balance 111. However, this thesis will 
confine itself only to its importance during cardiopulmonary bypass.
Despite these complex alterations in vascular dynamics, cardiopulmonary 
bypass has been advocated by Levy and Hug 112 as a suitable model for 
studying the circulation. This review will now concentrate on the various 
haemodynamic variables that have been used to monitor and measure the 
circulation during cardiopulmonary bypass.
MEASURES OF HAEMODYNAMICS
A variety of haemodynamic variables have been used to measure the 
systemic circulation during cardiopulmonary bypass. All but one of these 
variables are common to those employed in the intact cardiovascular system. 
Unlike the intact cardiovascular system, an estimate of the venous compliance 
can be obtained from the pump reservoir volume. In even greater contrast to the 
intact cardiovascular system, systemic blood flow  rate is determined and 
delivered mechanically rather than being a function of cardiac performance that 
has to be measured.
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Systemic arterial pressure
Extremes of systolic arterial pressure in either direction can have adverse 
effects on patient wellbeing. Of the two extremes, hypotension is the more 
common though hypertension is potentially far more catastrophic.
No consensus of opinion exists as to what level of systemic arterial 
pressure constitutes hypotension during cardiopulmonary bypass. Usually, it is 
stated in terms of mean arterial pressure. Some workers define hypotension as 
a mean arterial pressure less than 50 mmHg 9 whilst others use a level as low 
as 30 mmHg 10 63. Although there is no agreement as to what constitutes 
hypotension, its adverse effects on tissue perfusion are generally accepted and 
in particular, that cereberal and myocardial damage may occur9-io.63.ii3_
Even less agreement exists as to the level of systemic arterial pressure 
which constitutes hypertension during cardiopulmonary bypass. There is not 
even accord as to which variable to monitor, as systolic and mean arterial 
pressures are used in different centres. In general, vasodilators will be 
administered to patients when their mean arterial pressure exceeds 80-100 
mmHg. The major danger of hypertension during cardiopulmonary bypass is 
disruption of the aorta at the cannulation site. This complication is fortunately 
extremely rare as the consequences are dire. Vasodilating agents which have 
no anaesthetic action, such as phenoxybenzamine, phentolamine and sodium 
nitroprusside, are commonly used to control this hypertension.
During cardiac surgery, systemic arterial pressure is usually recorded 
directly via a cannula inserted into the radial artery. However, radial artery 
pressure may not always accurately reflect the aortic pressure, especially the 
svstolic pressure during rewarmina m . Aortic pressure must therefore be the 
most accurate site for measuring systemic arterial pressure but this is 
complicated to undertake during surgery. Also, movement of the manometer 
line may create artefacts and lead to inaccurate measurements. In any case, the 
mean arterial pressure at the radial artery is usually closely related to that within 
the aorta 114.
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Central venous pressure
Measurement of central venous pressure during cardiopulmonary bypass is 
of limited value as it merely indicates the state of venous return which is better 
measured directly by changes in reservoir volume. However, central venous 
pressure measurement comes into its own follow ing weaning from 
cardiopulmonary bypass when the reservoir volume is no longer available for 
determination of venous return. One exception to the case during 
cardiopulmonary bypass is the finding of unduly high central venous pressures 
which, in combination with poor venous return to the reservoir, indicates 
obstruction of the venae cava. If uncorrected, this is a serious complication as 
cerebral perfusion will be impaired. Venous hypertension should therefore be 
corrected as soon as possible. Most commonly, simple manipulation of the 
venous cannulae by the surgeon will rectify this problem.
Central venous pressure is measured directly during cardiac anaesthesia 
using a cannula inserted into the jugular or subclavian veins. Because venous 
blood is syphoned by gravity to the cardiopulmonary bypass pump, central 
venous pressure often drops to zero or below. Care has to be taken to avoid 
inaccuracies in measurements due to obstruction or kinking of the cannula which 
may occur during cross clamping.
One important advantage to measuring central venous pressure during 
cardiopulmonary bypass is that it enables the calculation of peripheral vascular 
resistance.
Peripheral vascular resistance
Although it is probably the most valuable indice of systemic perfusion, 
peripheral vascular resistance is not monitored routinely in every centre. As 
described in Chapter 4, peripheral vascular resistance is simply calculated using 
the mean arterial pressure, central venous pressure and pump flow  rate. But 
there is, as with mean arterial pressure, little agreement as to what value 
represents normal peripheral vascular resistance during cardiopulmonary bypass.
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Generally, it is believed that tissue perfusion is better at lower rather than higher 
levels of peripheral vascular resistance and that the progressive vasoconstriction 
has adverse effects on tissue perfusion 65.88,115 Thai vasoconstriction has 
adverse effects on tissue perfusion during cardiopulmonary bypass may only be 
a perceived truth as there is little evidence to directly link increased peripheral 
vascular resistance with impaired tissue perfusion. Indeed, the use of 
vasodilators, such as trimetaphan and sodium nitroprusside, during 
cardiopulmonary bypass do not result in any change in systemic oxygen 
uptake 46115.
Reservoir level
Venous compliance has been measured using forearm plesthmography 
during cardiopulmonary bypass by Gall and colleagues 116 who found it to be 
little affected. Assuming stable conditions, reservoir volume is also a measure of 
venous capacitance and therefore, venous tone. For this reason, 
cardiopulmonary bypass has been used as a model to study the effects of drugs 
on the venous system independent of any cardiac action 100 . 117 -1 2 0  However, 
during cardiopulmonary bypass ongoing haemorrhage leads to progressive 
blood loss. Also, partial obstruction of the venous lines can markedly reduce the 
venous return and so cause the reservoir level to fall. Vice versa, relief of 
venous obstruction can cause sudden increases in the reservoir level. 
Furthermore, very low reservoir levels require rapid fluid replacement or a 
reduction of pump flow rate to prevent massive embolism. Therefore, caution 
has to be taken in the interpretation of reservoir levels as a measure of venous 
compliance.
36
Chapter 2 Historical Review
EFFECTS OF CARDIOPULMONARY BYPASS ON HAEMODYNAMIC
VARIABLES
This section will review the effects of different aspects of cardiopulmonary 
bypass on the aforementioned haemodynamic variables. The effects of factors 
which remain uncertain will be highlighted.
Hypothermia
Hypothermia, by increasing the viscosity of blood, produces a rise in 
peripheral vascular resistance during cardiopulmonary bypass that may impair 
tissue perfusion 121. This haemodynamic disadvantage of hypothermia is, 
however, greatly outweighed by its metabolic benefits which have been 
discussed previously. Moreover, this adverse effect of hypothermia is 
counteracted by haemodilution.
Haemodilution
The use of a crystalbid or colloid priming solution produces haemodilution 
which is measured by reduction in haematocrit. As well as the advantages of 
avoiding a blood prime, for example transfusion reactions and infection, this 
reduction in haematocrit decreases the blood viscosity and counteracts the 
adverse effects of hypothermia which are discussed above 122.
Flow rate
It has long been recognised that peripheral vascular resistance is inversely 
related to flow  rate during cardiopulmonary bypass 34 123. However, there have 
been major changes in cardiopulmonary bypass technique over the decades. 
Not only are haemodilution, hypothermia and pulsatile perfusion now commonly 
employed but, as discussed ealier, flow rate is frequently reduced to low levels 
during hypothermic cardiopulmonary bypass. Considering its importance, the 
effect of flow  rate on peripheral vascular resistance has been insufficiently 
studied under present conditions of practice.
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Flow character
Along with its metabolic effects, a pulsatile flow  character has been stated 
by T ay lo r65 and Hickey, Buckley and Philbin 12 to be haemodynamically superior 
to a nonpulsatile one. The basis for this statement lies in the findings of many 
studies which have concluded that pulsatile perfusion results in a lower
peripheral vascular resistance than nonpulsatile flow  43-45,67.68.70.106 a s w ith the 
metabolic effects discussed earlier, some of these studies can be criticised 
because of the use of a higher flow  rate in the pulsatile than the nonpulsatile 
group, which must invalidate their findings 45,68,106 |f peripheral vascular
resistance is inversely related to flow rate, then the lower peripheral vascular 
resistance may be due to the use of a higher flow rate and not to pulsatile 
perfusion. Although fewer in number, some studies have been unable to 
demonstrate any haemodynamic differences between nonpulsatile and pulsatile 
perfusion 8 .4 7 . 7 1 , 72 .124  anc| one study even found peripheral vascular resistance to 
be raised when pulsatile perfusion was used 69. As discussed before, these 
differences in findings have been reconciled by Hickey, Buckley and Philbin 12 
on the basis that differences in flow  character only become apparent during low 
flow  rates. However, the effects of flow character on haemodynamic variables 
during hypothermic cardiopulmonary bypass remain unclear and they are
especially uncertain at the low rates of flow that are often used.
Acid-base management
Under normal conditions, acid-base balance is known to have important 
actions on the cardiovascular system yet few studies have considered its effects 
on systemic haemodynamics during cardiopulmonary bypass. Bove and 
co-workers, using a canine model, were unable to demonstrate any significant 
difference in haemodynamic variables during hypothermic cardiopulmonary 
bypass between pH and alpha-stat acid-base managements 125. Human studies 
using cardiopulmonary bypass at or near normothermia have had conflicting 
findings. Paterson found that hypocapnoea produced an increase in arterial
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pressure 84 whereas Springer and colleagues could demonstrate no significant 
difference in peripheral vascular resistance when arterial carbon dioxide tension 
was altered by 5 mmHg 83
The differences in the effects on systemic haemodynamic variables during 
cardiopulmonary bypass between alpha and pH-stat acid-base management 
have not been previously investigated. Acid-base management during 
hypothermic cardiopulmonary bypass is known to have important effects on 
cerebral blood flow  and as these have been reviewed previously, they will not 
be considered here 126. Instead, this review will now attend to  the effects that 
anaesthesia during cardiopulmonary bypass has on haemodynamic variables.
EFFECTS OF ANAESTHESIA DURING CARDIOPULMONARY BYPASS 
ON HAEMODYNAMICS
Cardiac anaesthesia’s effects on the intact cardiovascular system at 
normothermia have been extensively investigated. However, most attention has 
been paid to the effects of anaesthetic agents on the cardiovascular system 
before and after cardiopulmonary bypass and, in particular, their effects on the 
coronary circulation. Relatively little systematic enquiry has been made into the 
effects of anaesthesia on the vasculature during the abnormal conditions of 
hypothermic cardiopulmonary bypass when the heart is isolated from the 
circulation. This section will review the known effects of anaesthesia during 
cardiopulmonary bypass on systemic haemodynamic variables.
Some agents used for cardiac anaesthesia have marked haemodynamic 
effects in the intact cardiovascular system whilst others have but minimal 
actions 1617. Increasingly, it is being recognised that anaesthesia also has 
important haenr/odynamic effects during cardiopulmonary bypass 18. Moreover, 
these effects may not be limited to the period of cardiopulmonary bypass and 
may influence overall outcome following cardiac surgery 18. Therefore, the 
choice of anaesthetic agents may have important actions on the vascular 
system that could be used to advantage during cardiopulmonary bypass.
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Inhalational anaesthetics
Of the inhalational anaesthetic agents, halothane has been found by 
Norden not to reduce arterial pressure although it slowed the rate of increase in 
peripheral vascular resistance over the course of hypothermic cardiopulmonary 
bypass 88. Isoflurane has marked vasodilatory effects compared to halothane 
9192127. Therefore, there may be benefits in using isoflurane during hypothermic 
cardiopulmonary bypass as its vasodilatory action could be used to prevent or 
control hypertension. However, isoflurane’s effects on haemodynamic variables 
during cardiopulmonary bypass have not been previously studied in a systematic 
manner.
Neuromuscular blocking agents
Tubocurarine was one of the original neuromuscular blocking agents used 
during cardiac anaesthesia 85. Like other anaesthetic agents of its time, 
tubocurarine has largely fallen into disuse 20. One reason for this is that 
tubocurarine produces histamine release and ganglion blockade 128 and thereby 
causes hypotension and vasodilation 129. Tubocurarine has been largely 
superseded by modern neuromuscular blocking agents which were designed to 
have minimal cardiovascular side effects. Vecuronium and atracurium are two 
recently introduced neuromuscular blocking agents which are both noted for 
their minimal effects on the cardiovascular system 93 94. Although the 
haemodynamic effects of these agents have been extensively investigated, their 
effects during hypothermic cardiopulmonary bypass have been little studied, 
even though their pharmacodynamics are known to be altered in other ways at 
this time 13°-133.
Opioids
Opioids are sometimes used in high doses as the sole agent for cardiac 
anaesthesia although this practice is uncommon in the United Kingdom and 
Ireland 20. More often they are used during cardiopulmonary bypass as one 
component of balanced anaesthesia 20
40
Chapter 2 Historical Review
In the past, morphine was the standard opioid for cardiac anaesthesia 95. 
During cardiopulmonary bypass, Hsu, Hickey and Forbes 118 have found 
morphine to decrease peripheral vascular resistance and increase venous 
capacitance. These haemodynamic effects of morphine were not altered by 
prior administration of naloxone but were partially attenuated by promethazine 
and, therefore, they concluded that morphine's haemodynamic effects were 
mediated by histamine. Morphine is now less often used because, in the high 
doses that are usually employed for cardiac anaesthesia, it causes histamine 
release and so cardiovascular instability 95.
Fentanyl and more recently alfentanil, which cause little histamine release 
95 133, have largely replaced morphine. These opioids have been found to have 
minimal effects on the cardiovascular system and to be suitable agents for 
cardiac anaesthesia 95 134. However, there has been little systematic study of 
their effects on haemodynamic variables during cardiopulmonary bypass. This 
thesis will examine the haemodynamic actions of alfentanil.
Intravenous anaesthetics
Chlorpromazine is a neurolept agent with an alpha-adrenergic blocking 
action that was commonly used in the past during cardiopulmonary bypass. It 
has been found to be a vasodilator and to reduce peripheral vascular resistance 
during hypothermic cardiopulmonary bypass 121. Chlorpromazine is now 
infrequently used 20, perhaps because of its prolonged duration of action and the 
difficulty in reversing its effects. These effects may lead to cardiovascular 
system instability during the crucial period of weaning from cardiopulmonary 
bypass. Droperidol is another neuroleptic agent which is used during 
cardiooulmonarv bypass. Droperidol. in doses of 0.15 or 0.3 mqkq 1. produces 
arterial vasodilation and decreases peripheral vascular resistance during 
hypothermic cardiopulmonary bypass, as well as increasing venous capacitance 
117. Because it is a vasodilator, droperidol is used to treat hypertension during 
cardiopulmonary bypass though, like chlorpromazine, it has the disadvantage of
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having a prolonged duration of action.
The haemodynamic effects of a variety of other intravenous anaesthetics, 
including etomidate, propofol and thiopentone, during cardiopulmonary bypass 
have recently been investigated by Boer, Ros and Bovill 135 136 and they have all 
been found to decrease peripheral vascular resistance. Pauca and Roy have 
also studied thiopentone during hypothermic cardiopulmonary bypass and found 
that the hypotension was preceeded by an initial hypertensive response 137. 
They attributed the initial vasoconstriction to a peripheral effect and the 
secondary vasodilation to a central effect.
As most of the commonly used intravenous anaesthetics have been 
studied during cardiopulmonary bypass and found to cause vasodilation, this 
thesis will not examine this groups of anaesthetics.
STUDY DESIGN
Most commonly, parallel group comparisons have been used to study 
haemodynamic and metabolic variables during cardiopulmonary bypass. This 
form of study design, although sometimes necessary, has been criticised by 
Singh, Barratt-Boyes and Harris 47 as being inappropriate for comparison of size 
dependent variables such as systemic oxygen uptake. Relative to within group 
comparisons, between group studies result in considerable loss of sensitivity. 
Previous studies in humans have examined the effects of individual factors on 
haemodynamic and metabolic variables, none have considered whether these 
factors interact, either beneficially or detrimentally. Yet this is potentially 
extremely important as clinical cardiopulmonary bypass is constructed from a 
combination of techniques rather than one in isolation. Factorial experiments 
allow not only study of the main effects of individual factors but also the 
interaction between factors. For these reasons, a factorial study design should
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be valuable in cardiopulmonary bypass research 138.139 Factorial study designs 
have been applied successfully by Utley and colleagues 122 in an animal 
cardiopulmonary bypass experiment but they have not previously been used in 
human work. In this thesis, a factorial experiment was used in Chapter 5 to 
examine the effects of different cardiopulmonary bypass techniques, but was 
not used to study the effects of different combinations of anaesthesia because 
the increased complexity of multiple anaesthetic techniques could have 
adversely affected patient safety.
Another questionable aspect of most previous studies which have 
investigated the effects on haemodynamic and metabolic variables of the 
various components of cardiopulmonary bypass is that they have not controlled 
the anaesthesia employed. This failure may have confounded their findings as 
different techniques of anaesthesia may have existed between groups or even 
different depths of anaesthesia according to the quantities of drugs used.
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AIMS
From the foregoing review, it is apparent that the haemodynamic and 
metabolic effects of certain basic aspects of cardiopulmonary bypass remain 
unresolved or require re-evaluation in the light of present day practice. 
Furthermore, the haemodynamic and metabolic effects of modern cardiac 
anaesthetic agents during cardiopulmonary bypass remain largely unknown. 
Determination of the most effective combination of cardiopulmonary bypass and 
anaesthetic technique, in terms of haemodynamics and metabolism, should 
improve patient wellbeing during cardiopulmonary bypass and thereby, the 
ultimate outcome of cardiac surgery.
For the above reasons, it is hypothesised that cardiopulmonary bypass and 
anaesthetic technique have important influences on haemodynamic and 
metabolic variables during hypothermic cardiopulmonary bypass. This thesis was 
therefore undertaken to study the effects of the following factors on 
haemodynamic and metabolic variables : -
1. Cardiopulmonary bypass
a) flow  rate
b) flow  character
c) acid-base management
2 Anaesthesia
a) isoflurane
b) atracurium
c) alfentanil
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METHODS AND MEASUREMENTS
This chapter describes the methods and measurements that are common 
to all of the following studies. Those methods specific to individual studies are 
presented in their respective chapters. All studies were undertaken in Theatres F 
and G of Glasgow Royal Infirmary.
Ethical considerations
Approval for all studies was obtained from the Glasgow Royal Infirmary 
Ethics Committee. All studies were conducted according to the Declaration of 
Helsinki and in every case, informed consent was obtained from each patient 
before admission to every study.
Patient selection
Only patients scheduled for elective coronary artery bypass surgery by one 
specific surgical team were selected, with the exception of the study in Chapter 
6 when patients planned for heart valve surgery by the same team were also 
admitted. Patients with carotid artery and cerebro-vascular disease, poor left 
ventricular function, severe hepatic disease, renal failure or diabetes melitus 
were excluded.
Cardiopulmonary bypass
Following injection of heparin 3 m g .kg 1 into the right atrium, both venae 
cavae were cannulated with two straight polyvinyl bevelled and bell tipped 8mm 
diameter cannulae (American Bentley, Irvine, California, USA.). A right angled 
tapered cannula with a terminal diameter of 6 mm (Gambrio Dialysatoren KG, 
Henchigen, FRG.) was inserted into the aorta so that the tip pointed towards the 
arch.
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The cardiopulmonary bypass circuit consisted of a bubble oxygenator 
(BOS 10 or BOS 10 Plus, American Bentley.) and a roller pump (10-00-00, 
Stocked Instrumentes, Munchen, FRG.) which could be controlled to produce 
nonpulsatile or pulsatile perfusion using a pulsatile control unit (EC 26, Stocked 
Instrumentes.). When used in the pulsatile mode, the unit was set to deliver a 
pulse rate of 70.m in-1 with the pulse run time set to 50% of the total cycle 
length. With the exception of studies in Chapters 4 and 5, when flow  character 
was being examined, nonpulsatile perfusion was used in all studies.
The cardiopulmonary bypass circuit was primed with a mixture of lactated 
Ringers solution 2L, mannitol 20% 100 ml, potassium chloride 15 mmol and 
heparin 8000 units. An arterial filter (C1040, American Bentley.) and a GasSTAT 
cell (Cardiovascular Devices, Irvine, California, USA.) were inserted into the 
arterial line.
Arterial blood pH and carbon dioxide and oxygen tensions were measured 
during cardiopulmonary bypass using an inline m onitor (GasSTAT, 
Cardiovascular Devices.). Arterial pH was controlled by manipulation of the gas 
concentrations ( 0 2 100% and/or 0 2 95% and C 0 2 5%) and the flow  rate supplied 
to the oxygenator. Perfusionists were instructed, according to study protocols, 
to maintain arterial pH as close as possible to 7.4. The inline monitor was set 
either in the mode that measurements are displayed at the actual patient blood 
temperature for pH-stat acid-base management or in that which internally 
corrects the results to 37°C for alpha-stat acid-base management 140. Acid-base 
management was according to alpha-stat principles in all studies with the 
exception of those in Chapters 4 and 5 when it was alternated between pH and 
alpha-stat control as dictated by the study protocol.
Throughout the series of studies, the pump was regularly calibrated 
volumetrically with water at room temperature. The pump flow  rate during 
induction of hypothermia and rewarming was 2.4 L.m in-1.m-2. During stable
hypothermia the flow rate was reduced to and maintained at 1.6 L rmn 1.rn 2 in
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all studies with the exception of the studies in Chapters 4 and 5 when the flow  
rate was alternated between 1.5 and 2.0 L.mim1.rrr2.
Haemodynamic control
In all studies, isoflurane was administered up to a vaporiser setting of 3% 
before and after cardiopulmonary bypass when sodium nitroprusside or glyceral 
trinitrate IV were given to control systemic arterial pressure. All vasoactive drugs 
were discontinued at the start of cardiopulmonary bypass. Hypotension during 
cardiopulmonary bypass was defined as a mean systemic arterial pressure less 
than 35 mmHg measured at the radial artery and it was treated with boluses of 
methoxamine 2 mg IV as required to maintain the pressure equal to this level. A 
mean arterial pressure greater than 95 mmHg was identified as hypertension 
and it was corrected to this level using an infusion of sodium nitroprusside IV. 
Hypovolaemia was defined as a reservoir level less than 400 ml. If the 
haematocrit was 20% or greater, hypovolaemia was treated with lactated 
Ringers solution whereas, concentrated red cells were given if the haematocrit 
was less than 20%.
Blood sampling
Blood samples were aspirated by the author at the end of each 10 minute 
study period from the arterial and venous lines of the cardiopulmonary bypass 
circuit into glass syringes. Arterial blood was withdrawn from the arterial filter 
after discarding dead space blood. Venous blood was taken from a sampling 
port situated in the venous line immediately before its entry into the oxygenator. 
Air was excluded from the syringes and they were then capped and placed in 
iced water until analyses which were undertaken within one hour of sampling. 
All analyses were performed in duplicate by technicians who were blind to the 
study. The tw o measurements were averaged and this mean used in all 
statistical analyses.
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Blood oxygen content
The oxygen content of blood was measured using an elecrolytic method 
with a L e x -0 2-Con TL (Lexington Instruments, Waltham, Massachusetts, USA.). 
The accuracy of the instrument was verified against the Van Slyke method using 
a N a te lson  M icrogasom eter (650, Scientific  Industries, Springfie ld , 
Massachusetts, USA ). Before use in each patient the analyser was calibrated 
with air.
Systemic oxygen uptake
System ic oxygen uptake was calculated according to Fick’s principle 29 
using the difference in arterial and venous oxygen contents and the pump flow 
rate standardised for body surface area. The following formula was employed:
V 0 2 = (Ca02 -  C v02) x Q
Where:
V 0 2 = systemic oxygen uptake (ml.min hm -2)
C a 0 2 = arterial oxygen content (ml.L 1)
C v0 2 mixed venous oxygen content (m l.L-1)
Q = pump flow rate (L.min 1.m 2)
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Systemic oxygen delivery
Systemic oxygen delivery was calculated as the product of arterial oxygen 
content and pump flow  rate standardised for body surface area. The fo llow ing 
formula was employed :
D 0 2 = C a02 x Q
Where:
D 0 2 = systemic oxygen delivery (ml.min-1.m-2)
C a02 = arterial oxygen content (ml.L-1)
Q = pump flow  rate (L.m imLm-2)
Systemic oxygen delivery was calculated only in the study in Chapter 5 as 
the flow  was kept constant in all other studies and therefore, it would only be 
affected by a change in arterial blood oxygen content.
Haemoglobin concentration and oxygen saturation
Haemoglobin concentration and saturation of haemoglobin with oxygen 
were measured with an IL 282 CO-oxim eter (Instrumentation Laboratories, 
Lexington, Massachusetts, USA.). Routine quality control checks were 
performed (Levels 1, 2 and 3, Certain Advance, Ciba Corning Diagnostics Corp., 
Medfield, Massachusetts, USA.). The coefficients of variation for measurements 
of haemoglobin and haemoglobin oxygen saturation were respectively; 1.10%, 
0.58% and 0.61% and 0.98%, 0.01% and 0%.
Blood gases and acid-base
Bench measurement of oxygen and carbon dioxide partial pressures, pH 
and base excess were done on a Corning 178 (Ciba Corning Diagnostics Corp.)
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blood gas analyser. The blood gas analyser self calibrates automatically to one 
point half hourly and to two points every hour. Regular quality control checks 
were undertaken with tonometered samples (Levels 1,2 and 3, Certain Advance, 
Ciba Corning Diagnostics Corp.) and throughout the course of the studies, there 
was good electrode stability 141. All acid-base and blood gas results presented 
are those of the bench blood gas analysis measured at 37°C and uncorrected 
for patient temperature unless otherwise indicated.
Lactate concentration
Venous blood samples were analysed for lactate concentration. A portion 
of the venous sample was placed in sodium fluoride tubes, the plasma was then 
separated and stored at -20°C until later analysis for lactate concentration. 
Lactate concentration was measured using a method modified from Noll 142. 
Estimation was performed with an enzyme kit (149993, Boering Mannheim 
GmbH, Lewes, United Kingdom.) which was adapted for use on a centrifugal 
analyser (C400, Centrifichem, Baker Instruments, Windsor, United Kingdom.). 
The coefficients of variation for the analyses at 0.5, 1.0 and 2.0 mmol.L 1 were 
respectively; 0.1%, 0.5% and 2.68%.
Haematocrit
Packed cell volume was measured using a microcapillary method. Samples 
were centrifuged for 10 minutes before being read using a graduated scale 
(Micro-haematocritometer, Hawksley and Sons Ltd, England).
Reservoir volume
At the end of each study period the volume of blood in the oxygenator plus 
that, if any, in the cardiotomy suction reservoir was noted as the reservoir 
volume.
Isoflurane during cardiopulmonary bypass
In all studies in which isoflurane was administered during cardiopulmonary 
bypass (Chapters 6-8), it was given via the same vaporiser (Isotec Mk3) 
inserted into the gas supply line to the oxygenator. The output of the vaporiser
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was measured with a calibrated portable interference refractometer (Riken Keiki 
Instrument Co, Ltd, Tokyo, Japan). At a setting of 5%, the isoflurane output was 
4.20%, at a setting of 2% it was 1.54% and at 1%, it was 0.77%.
Isoflurane concentration
Arterial blood samples were analysed for isoflurane concentration in all 
studies, except Chapters 4 and 5, using the fo llow ing method. One millilitre of 
blood was added to carbon tetrachloride (analar grade), to which chloroform 
(analar grade) had previously been added, in a 4ml glass bottle. The chloroform 
acted as internal standard in the calibration. The bottle was roller mixed for 20 
minutes and it was then centrifuged. One microlitre was then removed from the 
bottle for analysis. The chromatograph was a Pye Unicam 104 series flame 
ionisation detector fitted with a 3 m by 4 mm glass column packed with 5% 
OV-101 (Phase Separation Ltd.). The operating conditions were: column 
temperature, 353 K; detector temperature, 423 K; nitrogen flow, 50ml.min 1, 
hydrogen flow, 50 ml.min-1 and air flow, 500ml.min 1. Calibration was performed 
using standard solutions made from a gravimetrically prepared stock solution of 
isoflurane in carbon tetrachloride. Peak height ratios of isoflurane to chloroform 
in the standard solutions were determined and plotted against the 
corresponding isoflurane concentration. This graph was then used to convert the 
extracted samples peak height ratios to isoflurane concentration. The extraction 
efficiency was 100%. The accuracy of the method was checked using spiked 
blood samples. The coefficient of variation for the analyses were 5.4% at a 
concentration of 40 ug.mH and 4.3% at a concentration of 100 ug.ml 1.
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A COMPUTERISED SYSTEM FOR THE STUDY OF OXYGEN 
UPTAKE AND HAEMODYNAMICS DURING  
CARDIOPULMONARY BYPASS
INTRODUCTION
Before undertaking accurate haemodynamic and metabolic investigation 
during cardiopulmonary bypass, it is first necessary to ensure stable conditions. 
As discussed in Chapter 2, there are four fundamental aspects of 
cardiopulmonary bypass technique which may influence haemodynamics and 
metabolism; these are pump flow rate, flow  character, temperature and 
acid-base management. Employment of a pump which will produce flow  rates 
w ith reasonable accuracy and reliability is essential and modern roller pumps, if 
regularly calibrated, will fulfil this requirem ent143. The flow  character used, that is 
either nonpulsatile or pulsatile perfusion, is important but quantification of the 
pulse pressure generated is also necessary 12. Unlike flow  rate and character, 
which are determined by the relevant pump controls, temperature and acid-base 
control require the perfusionist to measure, decide on the alteration necessary 
and then to effect the change needed to produce the desired values. During 
cardiopulmonary bypass, the perfusionist performs multiple tasks and can be 
distracted by events of more immediate importance than temperature and 
acid-base management 144. Thus the accuracy of temperature and acid-base 
control, although generally acceptable for clinical purposes, may be less than 
satisfactory for research purposes.
With regard to haemodynamic measurement during cardiopulmonary 
bypass, single readings may be prone to inaccuracy both because of artefacts,
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which are common, and also because there are spontaneous oscillations in 
systemic arterial pressure 145. Using the mean of a series of sequential 
recordings performed over a specific period of time should overcome this 
problem and thus improve the reliability of measurements. Although this would 
be a difficult task to perform manually, computers are well suited to the rapid 
acquisition of data 144.
For these reasons, a computerised system was developed which would 
not only make repeated recordings of haemodynamic, temperature and arterial 
pH data, but also facilitate enhanced thermostatic and acid-base control. The 
aim of this study was to evaluate the performance of the computerised system.
SYSTEM DESIGN
The system (Figures 2 and 3) consisted of a GasSTAT inline blood gas 
monitor (Cardiovascular Devices) and a Kone Patient Data Monitor (565, Kone 
Corporation, Ospoo, Finland.) linked to an Apple 11 e personal computer (Apple 
Computer Inc., Cupertino, CA, USA.). The inline blood gas monitor was 
mounted on the cardiopulmonary bypass machine and was connected to, but 
electrically isolated from, the computer.
The inline monitor has recently become commercially available (Figure 4). 
It’s function is based on the novel principle of chemofluorescence. Sensors, 
whicn consist of spots of chemical dyes, are placed inline in the 
cardiopulmonary circuit. When stimulated with pulses of light, the dyes fluoresce 
in proportion to the concentration of carbon dioxide, oxygen and hydrogen ions 
present in the blood. The fluorescence is transmitted to the monitor by fibreoptic 
cable where it is quantified by a photodetector. A microprocessor then converts 
the information, as appropriate, into pH units or mmHg which is then displayed 
and transmitted to a serial interface port. Incorporated within the monitor's 
connector is a thermistor which allows measurement of blood temperature and
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this information is also displayed and transmitted to the serial interface port. On 
checking against an accurate mercury in glass thermometer, the monitor was 
found to consistently over-estimate the temperature by about 0.6°C. The 
monitor can be switched to display the results at the actual blood temperature at 
which it measures the blood gases or corrected to 37°C. This allows the use of 
pH or alpha-stat acid-base management respectively H0.
The monitor was set to transmit data every 6 seconds at a Baud rate of 
9600. The signal is transmitted as TTL levels (0-5 Volts) and therefore, a TTL to 
RS-232 converter was built to convert it into RS-232 standard levels to allow 
interface with the computer.
Systemic arterial and central venous pressures were measured via 
cannulae inserted percutaneously into the radial artery (20g Teflon cannula, 
Quick Cath, Travenol Laboratories Ltd, Thetford, UK.) and internal jugular vein 
(7g cannula, Arrow International Inc., Reading, Pa, USA.). The same transducers 
(Trantec 800, Bentley, Irvine, California, USA.) and Patient Data Monitor were 
used in all patients. Before use, transducers were zeroed and manometrically 
calibrated using a column of saline that was of a known height. Transducers 
were then maintained manometrically zeroed to the mid-axillary line throughout 
the operation. Nasopharyngeal temperature was measured using the 
temperature module of the Patient Data Monitor and a thermistor temperature 
probe (YST 700, Yellow Springs Instrument CO., Yellow Springs, Ohio, USA.) 
which was confirmed as accurate against a mercury in glass thermometer.
Information from the Patient Data Monitor is transmitted as an RS-232 
signal at 9600 baud. Transmission is triggered by QRS complexes on the 
electro-cardioaraph. During a large part of cardiopulmonary bypass the heart is 
maintained in asystole therefore, an electro-cardiograph simulator was built to 
produce a signal at the rate of one hertz. A program was developed for the 
computer which allowed real time haemodynamic, temperature and blood gas 
data to be shown on the visual display unit. The program also stored data from 
the previous 10 minutes and calculated a running mean with one standard
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deviation for the arterial temperature and pH. This information was shown on 
the visual display unit. When the investigator was satisfied that stable 
conditions had been maintained, he signalled the computer. Data from that 
period were stored on magnetic disc and the real time data were printed as hard 
copy. A 10 minute duration was chosen because of the limited amount of time 
available during stable hypothermia. A longer duration might have improved data 
reliability but would have reduced the number of patients in which two or more 
periods could be achieved for within patient comparison. The program also 
allowed stored data to be edited and a hard copy to be printed at a later time. It 
enabled calculation from stored data of the mean and one standard deviation for 
systolic, diastolic and mean arterial pressures, arterial pulse and central venous 
pressures and. following entry of pump flow  rate, the peripheral vascular 
resistance for each period. Peripheral vascular resistance was calculated using 
the follow ing formula:
PVR = (MAP -  CVP) x 80 
Q
Where; PVR = peripheral vascular resistance (dynes.s.cnrr5)
MAP = mean arterial pressure (mmHg)
CVP = central venous pressure (mmHg)
Q = pump flow rate (L.mm 1)
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METHODS
Clinical evaluation of the system was undertaken during the course of the 
studies which are outlined in detail in Chapter 5. It was planned to produce, with 
the exception of the variable under investigation, three 10 minute periods of 
stable hypothermic cardiopulmonary bypass for study in each of 24 consecutive 
patients. Stable cardiopulmonary bypass was defined as both arterial and 
nasopharyngeal temperatures between 27-29°C, arterial pH between 7.38-7.42 
and constant flow  rate and character.
At the end of each 10 minute period, blood samples were withdrawn from 
the arterial line of the cardiopulmonary bypass circuit and measured for pH using 
a bench blood gas analyser as described in Chapter 3. A comparison of pH, as 
measured by the inline blood gas monitor at the end of each period, was made 
with the results obtained from the bench blood gas analyser using linear 
regression.
Variables recorded by the computer were analysed using estimation of 
confidence limits. Results are presented as means with 95% confidence limits in 
parenthesis. The calculated means of each parameter from every period were 
used in analysis of within patient changes.
RESULTS
Data acquisition
Because of limited time at stable hypothermia, only 12 of a possible 24 
tmrd periods were obtained gwing a total of 60 periods fui inclusion in the 
analysis. The average number of readings in each period was 73.5 (95% CL 
70.1, 77.0). After exclusion of data outwith three standard deviations of the 
mean or zero recordings in any parameter except central venous pressure, the
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average number of acceptable readings was 71.2 (95% CL 67.3, 75.1). For one 
patient, in all three periods, only interm ittent readings were recorded because of 
a loose electrical connection. Occasionally, isolated single zero recordings 
occurred in a few  periods and an occasional reading was found which was 
either markedly lower, or more usually, markedly higher than tnat wmcn either 
immediately preceded or followed it.
Thermostatic control
In all but five periods, the 95% confidence limits for the means of arterial 
temperature fell within the preset target range (27-29°C). The 95% confidence 
limits of the means in those periods lay between 26 and 27°C and occurred 
during the first period of study in five separate patients. Overall, there was a 
small but significant mean within patient increase in arterial temperature from 
Period 1 to 2 of 0.21 (95% CL 0.07, 0.35)°C and a small decrease from Periods 2 
to 3 of -0.13 (95% CL -0.05, -0.21)°C. Between Periods 1 and 3, there was no 
significant change [ -0.003 (95% CL -0.205, 0.198)°C]. Without exception, all the 
95% confidence limits for the means of nasopharyngeal temperature fell within 
the preset target range (27-29°C). There was a small but nonsignificant mean 
within patient decrease in nasopharyngeal temperature from Periods 1 to 2 of 
-0.13 (95% CL -0.27, 0.00)°C, from Periods 2 to 3 of -0.12 (95% CL -0.33, 
0.08)°C and Periods 1 to 3 of -0.19 (95% CL -0.43, 0.05)°C. Nasopharyngeal 
temperature was on average 0.60 (95% CL 0.48, 0.72)°C higher than arterial 
temperature.
Acid-base management
During the studies described in Chapters 5 and 6, comparison of arterial pH 
measurements made by the inline blood gas monitor with bench blood gas 
analyses of blood samples found a significant, though less than complete, 
correlation (Figure 5).
In only 43 of the total 60 periods did the 95% confidence limits of the 
means for arterial pH fall within the prescribed target range (7.38 -  7.42). There
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were small, but nonsignificant, within patient increases in arterial pH of 0.007 
(95% CL -0.009, 0.024) from Periods 1 to 2, of 0.005 (95% CL -010, 0.021) from 
Periods 2 to 3 and of 0.006 (95% CL -0.016, 0.028) from Periods 1 to  3. 
Alteration in pump flow  rate and flow  character had no significant effect on the 
arterial pH measurements made by the inline monitor, unlike alteration in 
acid-base management between pH and alpha-stat which produced a mean 
difference in pH of 0.026 (95% CL 0.006, 0.046) (Figure 6). In these same 
periods, the mean arterial pH, as measured by the inline blood gas monitor, 
during pH-stat acid-base management was 7.404 (95% CL 7.384, 7.424) 
whereas it was 7.381 (95% CL 7.357, 7.405) during alpha-stat control.
DISCUSSION
The main findings of this study are that the computerised system 
functioned well in recording data and facilitated good control of temperature but 
not of arterial pH.
Data acquisition
Data collection and recording were good with the one exception when a 
fault developed in a connector. Occasional isolated readings were recorded 
which were obviously spurious. During pressure measurements, these most 
likely originated from inadvertent flushing of the manometer lines or resonance 
in the lines produced by accidental movement. With nasopharyngeal 
temperature measurements, the use of diathermy possibly accounts for the few  
erroneous recordings. Zero recordings are more difficult to explain but may be 
due to differences in the tim ing of data collection from online monitors. Both 
these forms of error were simply identified and removed w ithout affecting the 
overall validity of the data which were otherwise very consistent. This acquisition 
of frequent recordings from multiple measured parameters demonstrates that
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computers, as has been previously suggested 144, are an effective tool for this 
purpose.
Thermostatic control
Excellent nasopharyngeal temperature control was obtained using this 
system, although arterial temperature control was not quite as good. The 
periods of low arterial temperature can be explained by the necessity of cooling 
the arterial blood to lower than the desired body temperature in order to induce 
hypothermia rapidly. Lack of observation on the part of the investigator and 
pump technician account for their occurrence and emphasise the potential for 
error in studies where investigator observation alone is used. Because 
nasopharyngeal temperature was always brought into range before arteriai, the 
choice of displaying arterial temperature to the investigator as a running mean 
with one standard deviation appears justified as arterial temperature stability 
indicated nasopharyngeal temperature stability but not vice versa. The failure to 
achieve good arterial control during some first periods of study, combined with 
fluctuations of temperature within the preset range, highlights the need for a well 
considered study design. As has been previously stated by Davies, 
Paramelzhagen and Harris 146, the study design must control any influence that 
fluctuations in temperature or other such variables m ight have on 
haemodynamics and metabolism during the course of cardiopulmonary bypass.
The use of only tw o sites for temperature measurement to  determine 
stable hypothermia is perhaps open to criticism as there are known to be many 
temperature gradients within the body during hypothermic cardiopulmonary 
bypass. Temperature monitoring at multiple sites, for example muscle, rectal 
and tympanic membrane, would possibly have improved reliability in 
determ ining and maintaining stable hypothermia. However, it is only w ith an 
animal model that true thermostatic stability can be achieved 52 and furthermore, 
nasopharyngeal temperature has been found to accurately reflect venous, 
oesophageal and hepatic temperatures during steady state hypothermic
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cardiopulmonary bypass in man 146. Moreover, maintaining both arterial and 
nasopharyngeal temperatures within the same small preset range for 10 minutes 
must indicate good thermal stability and, with a few  exceptions, it proved a 
reliable and repeatable method.
Given the above qualifications, good thermostatic control was achieved 
using this system in the greater majority of periods. This is partially a reflection 
on the accuracy of temperature monitoring but more importantly, due to the 
capacity of the oxygenator’s heat exchanger to effect control. This is in contrast 
to acid-base control which was generally poor because of less than accurate 
m onitoring and only a limited capacity to effect control.
Acid-base management
One advantage of using the GasSTAT monitor for comparative 
investigation of pH and alpha-stat methods of acid-base management, is that 
w ith both methods the perfusionist aims for the same target range. Thus, no bias 
is introduced as might be the case if different values were used. However, if 
good acid-base control had been achieved there should have been no 
significant within patient changes in arterial pH. This was indeed the case where 
acid-base control was kept constant and either pump flow  rate or flow  character 
were alternated. Nevertheless, there was a small but significant difference, 
measured by the inline blood gas monitor, between pH and alpha-stat 
acid-base management. The 95% confidence limits of the means during pH-stat 
control approximated to the target range, whereas during alpha-stat control they 
overlapped at the lower end of the range. This implies that the latter was more 
difficult to  attain. Also, the low success rate in achieving satisfactory control of 
pH was a surprising finding as it would be expected that inline pH monitoring 
would enable continuous accurate measurement of pH and so facilitate more 
effective control 141147. The explanation for this poor control is tw o  fold. Firstly, 
correlation between pH as measured by the inline blood gas m onitor and bench 
blood gas analysis was less than complete which may be attributed to 
differences in sites of measurement, problems with temperature correction ana
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systematic errors by the inline blood gas monitor 141,147 Secondly, and more 
importantly, the type of bubble oxygenator employed has gas exchange 
characteristics during hypothermia which lead to poor arterial pH control, 
especially if an alpha-stat approach is taken to acid-base management 140,148 a  
membrane oxygenator would have enabled better acid-base control but would 
have required the use of an extra roller pump to produce pulsatile perfusion. 
Since this study was undertaken bubble oxygenators which are designed to 
enable improved control of arterial pH during alpha-stat acid-base management 
have become commercially available i40.
In conclusion, the computerised system functioned well as a recording 
device. However, in terms of improved thermostatic and arterial pH control, the 
system only performed well if the method of monitoring was accurate and the 
means of effecting control was good.
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CHAPTER 5
CHANGES IN  HAEMODYNAMIC AND METABOLIC 
VARIABLES DURING HYPOTHERMIC 
CARDIOPULMONARY BYPASS:
EFFECTS OF FLOW RATE, FLOW CHARACTER AND 
ACID-BASE MANAGEMENT
METHODS
Study Design
A factorial study design was employed 138,139 patients were randomly 
allocated to one of three groups of eight. One group studied alternation in flow  
rate between 1.5 and 2.0 L.min-1.m-2, another group examined flow  character, 
which was either nonpulsatile or pulsatile, and a third group investigated 
acid-base management, which was either according to  pH or alpha-stat 
principles. Each group was constructed of two subsets that were identical in 
structure except that the order of investigation was reversed. A subset 
contained the four possible combinations of other variables under examination 
and these were kept constant throughout the study periods. Patient data was 
only accepted for analyses if a minimum of tw o periods had been completed 
before rewarming was started. Should this requirement not be achieved, then 
the next patient sequentially was studied.
Anaesthesia
Patients received their usual medication on the day of surgery. 
Premedication was with lorazepam 2-4 mg orally on the night prior to surgery 
and temazepam 20-50 mg orally approximately one hour before surgery.
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Anaesthesia was induced w ith fentanyl 5 ug.kg-1 and a sleep dose of 
midazolam IV. Neuromuscular blockade was obtained with vecuronium 0.15 
mg.kg-1 IV. The trachea was intubated and the lungs were ventilated with 
oxygen (50%) and nitrous oxide (50%) to  obtain eucapnoea. Anaesthesia was 
maintained with fentanyl 0.1 ug.kg-1.min-1 and neuromuscular blockade was 
continued with vecuronium 2.5 ug.kg-1.min-1 IV throughout the operation.
Statistical analysis
Data was analysed using statistical modelling and factorial analysis of 
variance on a main frame computer with a GLIM program 149. Because the 
groups construction were heterogeneous whereas the induced changes were 
homogeneous, results are presented as mean differences. Ninety five percent 
confidence limits of the means (95% CL), probability value (p) or F-statistic (F) 
are given in parenthesis where appropriate.
RESULTS 
Patient details
Twenty seven patients were investigated although only 24 were admitted 
to the study because the minimum of tw o periods were not completed in three 
of them. Demographic details and relevant durations are given in Table I. All 
patients were receiving one or more of the follow ing anti-anginal therapies; 
atenolol, propanolol, isosorbide nitrate, nifedipine and glyceryl trinitrate (sub­
lingual and transcutaneous). Because of the short time clinically available at 
stable hypothermia only 10 of a possible 24 third study periods were obtained. 
These were all included in the analyses.
Thermostatic control
As described in Chapter 4, good overall temperature control was achieved.
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Table I. Demographic details and durations.
Mean Standard deviation
Sex (F/M) 3/21 -
Age (yr) 54 9.2
Weight (kg) 76.1 9.4
Height (m) 1.71 0.06
Surface area (m2) 1.87 0.14
Cardiopulmonary bypass (min) 98 23
Cross clamp (min) 56 14
Chapter 5 Flow rate, flow  character and acid-base
Acid-base management
Analyses of the arterial pH results (Table II), as measured by bench blood 
gas analyser at 37°C and uncorrected for patient temperature, in periods of pH 
and alpha-stat acid-base management revealed the 95% confidence limits of 
the means to be respectively; 7.216, 7.250 and 7.325, 7.363. As these limits did 
not include the expected target values for pH-stat (7.27) and alpha-stat (7.40) 
acid-base management, arterial pH results were treated as a continuous 
regression variable in all further analyses.
Metabolic variables
Systemic oxygen uptake. Multiple statistical modelling of the systemic 
oxygen uptake results (Table III) from all patients found that the simplest and 
most significant model, which described the data, included only the individual 
patient and flow  rate. Neither flow character, arterial pH nor stage during the 
course of cardiopulmonary bypass (i.e. Period 1, 2 or 3) were included in the 
model. Alternation in flow  rate between low and high (1.5 and 2.0 L m in -1.m-2) 
resulted in a mean change in systemic oxygen uptake of 18 (95% CL 7, 30) 
m l.m in-1.m-2 (Figure 7). Systemic oxygen uptake was not significantly affected 
by alternation of flow  character between nonpulsatile and pulsatile perfusion (-4  
[95% CL -16, 7] ml.min-1.m-2) nor with variation in arterial pH ( -2  [95% CL -12, 
8] m l.m in-1.nrr2 per 0.1 pH unit) (Figures 7 and 8).
Systemic oxygen de/ivery. Analyses of the systemic oxygen delivery results 
(Table III) revealed that the simplest significant model to describe the data 
included only the individual patient and flow  rate. The mean within patient 
increase in systemic oxygen delivery from low to high flow  rate being 82 (95% 
CL 66, 98) m l.m in-1.m 2. No significant effects on systemic oxygen delivery 
resulted when flow  character or arterial pH were alternated (16 [95% CL -27, 6] 
ml.min- 1.m-2 and -3 [95% CL -16, 10] m l.m in 1.m 2 per 0.1 pH unit respectively).
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Blood oxygen variables. Modelling of the data for the measured blood 
oxygen variables (Table IV) found that som e were significantly affected by 
alternation in flow  rate whilst others were not. M ixed venous blood oxygen 
content, saturation and tension were all significantly higher at 2.0 compared to 
1.5 L.min Tm-2 (F = 5.51, 18.37, and 20.88; critical value = 4.17) whereas arterial 
blood oxygen content, saturation and tension and oxygen extraction were not 
significantly affected (F = 4.08, 3.99, 1.37, 0.01 ; critical value oxygen saturation = 
4.21, others = 4.17). However, the increases in both arterial blood oxygen 
content and oxygen extraction approached significance.
No significant changes in either the measured arterial and m ixed venous 
blood oxygen variables nor oxygen extraction were found to  occur w ith 
alternation of flow  character, arterial pH or w ith stage during cardiopulmonary 
bypass.
Haemoglobin concentration. Statistical m odelling of the haemoglobin 
concentration data (Table IV) found no significant relationships w ith  flow  rate, 
flow character and arterial pH nor w ith  stage during cardiopulmonary bypass.
Base excess. Modelling of base excess data (Table II) dem onstrated a 
strongly significant relationship between base excess and arterial pH (F = 83.68, 
critical value = 4.28) although the magnitude of the effect was very small. No 
significant relationships were found between base excess and alternation of 
flow rate or flo w  character nor w ith stage during cardiopulmonary bypass.
Lactate concentration. Modelling of plasma lactate concentrations (Table II) 
found no significant relationship w ith  flow  rate, flow  character or arterial pH. In 
all patients there was a small but significant decrease in the average lactate 
concentration during the course of cardiopulmonary bypass. There was a mean 
decrease in lactate concentration of 0.17 (95% CL -0.01. 0.34) m m ol.L-1 from 
Periods 1 to  2, 0.25 (95% CL -0.05, 0.55) m m ol.L-1 from Periods 2 to  3 and 0.42 
(95% CL 0.17, 0.65) m m o l.L 1 from Periods 1 to  3.
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Haemodynamic variables
Pu/sepressure. Examination of systolic and diasto lic arterial pressures (Table 
V) revealed that the mean pulse pressure during pulsatile perfusion was 23.7 
(95% CL 19.3, 28.0) mmHg. However, there was a mean pulse pressure of 14.1 
(95% CL 12.1, 16.0) mmHg during nonpulsatile perfusion. The mean within 
patient change in pulse pressure produced by alternating flow  character 
between nonpulsatile and pulsatile was 11.5 (95% CL 5.9, 17.1) mmHg. Because 
of the sizeable pulse pressure during periods of nonpulsatile perfusion and a large 
variability in pulse pressure during periods of pulsatile perfusion, pulse pressure 
was treated as a continuous regression variable in the analyses of 
haemodynamic variables.
Mean arteria/  pressure. Within patient changes in mean arterial pressure 
produced by alternations in pump flow  rate, flow  character and arterial pH are 
plotted in Figure 9. Analyses of mean arterial pressure data (Table V) found, 
when all other variables were excluded, that both patient and stage were 
individually significant (F = 8.323). When all variables under study w ere  included 
in the model, only flow  rate was found to  have a significant e ffect on mean 
arterial pressure (F = 4.765, critical value = 4.184). If only patient stage and flow  
rate were fitted  to  the model, the com bined effects of flow  character and arterial 
pH upon mean arterial pressure were not significant (F = 0.65, critical value = 
3.334). On average, mean arterial pressure was 7.2 (95% CL 1.6, 12.9) mmHg 
higher at 2.0 com pared to  1.5 L .m in-1.m-2.
Mean arterial pressure increased on average from  Period 1 to  2 by 9.4 
(95% CL 5.8, 13.0) mmHg, from Period 1 to  3 by 15.7 (95% CL 10.6, 20.9) m mHg 
and from Period 2 to 3 by 6.3 (95% CL 1.2, 11.4) mmHg. iabulatiori of the 
average values of mean arterial pressure for all six com binations of flow  rate 
and stage during pH and alpha-stat control (Table VI) dem onstrates not only the 
main effects of stage and flow  rate but also, interaction between arterial pH and
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Table VI. Averaged mean arterial pressures (mmHg) 
for all combinations of flow  rates and study periods 
during a) pH -sta t and b) Alpha-stat acid-base 
management.
a) pH -stat 2.0 L.m in-1.m-2 1.5 L.m in-1.m-2
Period 1 58 53
Period 2 63 58
Period 3 72 67
b) Alpha-stat
Period 1 58 53
Period 2 72 66
Period 3 76 71
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stage during cardiopulmonary bypass. Little or no difference in mean arterial 
pressure exists between attem pted pH and alpha-stat acid-base management 
during Period 1, but by Period 2, mean arterial pressure is higher w ith alpha than 
pH-stat control and this interaction is continued in Period 3.
Central venous pressure. Analyses of the central venous pressure data (Table 
V) demonstrated no significant relationships w ith  any of the variables 
investigated nor w ith stage during cardiopulmonary bypass.
Peripheral vascular resistance. W ithin patient changes in peripheral vascular 
resistance resulting from alternation in flow  rate, flow  character and arterial pH 
are plotted in Figure 10. M odelling of the peripheral vascular resistance data 
(Table V) found that if all other variables were excluded, patient and stage 
during cardiopulmonary bypass w ere individually significant (F = 10.706). When 
the variables under study were fitted to the model, only flow  rate was found to  
have a significant effect on peripheral vascular resistance (F = 15.892, critical 
value = 4.184). When only patient, stage and flow  rate were included in the 
model, the com bined effects of flow  character and arterial pH w ere 
nonsignificant (F = 1.745, critical value = 3.334). Tabulation of the average 
peripheral vascular resistance for all six com binations of flow  rate and stage 
(Table VII) shows that there were mean increases from Period 1 to  2 of 239 
(95% CL 135, 343) dynes.s.cm -5, from Period 1 to  3 of 324 (95% CL 175, 473) 
dynes.s.cm~5 and from Period 2 to  3 of 85 (95% CL -64, 234) dynes.s.cm -5. 
Also, there was a mean increase in peripheral vascular resistance of 316 (95% 
CL 152, 480) dynes.s.cm -5 at the low compared to the high flow  rate. However, 
no significant interaction between these variables was found.
A significant correlation between within patient changes in peripheral 
vascular res istance and contem poraneous system ic oxygen uptake 
measurements which w ere  produced by alternation in pump flow  rate betw een 
high and low was found (Figure 11).
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Figure 10. The e ffec t of alternating flow  rate between low and high (1.5 and
2.0 L.min 1.m 2), flo w  character between pulsatile and nonpulsatile perfusion 
and acid-base m anagem ent between pH and alpha-stat control (pHA and 
pH37) on peripheral vascular resistance (PVR). Closed circles represent 
changes betw een Periods 1 and 2 and open cirles changes between Periods 
2 and 3. Vertical bars represent 95% confidence limits for the mean change.
Table V II. Averaged peripheral vascular resistances 
(dynes, s. cm -5) for all com binations of flow  rates and 
study periods.
2.0 L.m in-1.m-2 1.5 L.m in-1.m-2
Period 1 1269 1585
Period 2 1508 1823
Period 3 1593 1908
a  Vo? [ml. m irr1 m 2)
T 50
-- 40
\  oN
N\  •  + 3 0
\
\
\
\
*  o \  •  + 2 0
No \ \
\
\  - -  10 
\
-1000 -500
a P.V.R. [dynes, s. cm- 5 ]
y = 7,3 + [ -0.035x3  
r = 0.648
p < 0 .0  1
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Figure 11. The re la tionsh ip  b e tw e e n  changes in system ic oxygen  uptake ( V 0 2) 
and peripheral vascular res is tance  (PVR) produced by a lternating  the f lo w  rate 
between 1.5 and 2.0 L .m in 1.m 2. C losed  circles represent changes b e tw e e n  
Periods 1 and 2 and open c irles  changes be tw een  Periods 2 and 3.
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Haematocrit. Over all periods, the mean haematocrit was 27.6 (95% CL 26.4, 
28.8)%. Analyses of the haematocrit results found that the simplest significant 
model which described the data included patient, stage, pump flow  rate and a 
factor for interaction between stage and pump flow  rate. Tabulation of the 
average haematocrit values for all six com binations of stage and pump flow  rate 
(Table VIII) shows that there were minimal differences in haematocrit during 
Periods 1 and 2 but by Period 3 haematocrit at the high flow  rate was 
approximately 3% less than the low flow  rate.
Reservoir vo/ume. A significant interaction between stage of study period 
during cardiopulmonary bypass and flow  rate was found (Table IX). Average 
reservoir volumes were less at the high com pared to  the low flow  rate during 
Periods 1 and 2 but the situation was reversed during Period 3.
Vasoactive drugs. There were no significant relationships between sodium 
nitroprusside or methoxam ine adm inistration and any of the variables 
investigated. However, there was an overall tendency for greater m ethoxam ine 
usage in Period 1 (Table X) and greater sodium nitroprusside usage in Periods 2 
and 3.
DISCUSSION
The outstanding findings of this study are that system ic oxygen uptake and 
peripheral vascular resistance were significantly affected by alternation in flow  
rate between 1.5 and 2.0 L.m in-1.m-2 but not by alternation of flow  character or 
arterial pH.
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Table VIII. Averaged haematocrits (%) for all
com binations of flow  rate and study periods.
2.0 L.m in-1.m-2 1.5 L.m in-1.m-2
Period 1 27.2 27.2
Period 2 27.5 27.6
Period 3 26.5 29.5
Table IX. Averaged reservoir volumes (m l) for all
com binations of flow  rates and study periods.
2.0 L.min 1.nrr2 1.5 L.m in-1.m-2
Period 1 790 1309
Period 2 755 1185
Period 3 946 736
Table X. M ethoxam ine (M) and sodium nitroprusside (SNP) adm inistration.
Patient Period 1 Period 2 Period 3
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
17
18
19
20
21
22
23
24
2.0 L.m in-1.nrr2 
0 
SNP 
0 
0
1.5 L.min Tm 2 
0 
M 
0 
M
Pulsatile
0
0
0
0
Nonpulsatile
0
0
0
0
pH -sta t
M
0
0
0
A lpha-stat
0
SNP
SNP
0
1.5 L.m in-1.m-2 
0 
SNP 
0 
0
2.0 L.m in-1.nrr2 
SNP 
0 
0 
0
Nonpulsatile
0
0
0
0
Pulsatile
SNP
SNP
0
SNP
Alpha-stat
0
SNP
0
SNP
pH-stat
0
SNP
SNP
0
2.0 L.m in-1.m-2 
SNP
SNP
1.5 L.m in-1.m~2 
SNP 
0
0
Pulsatile
0
Nonpulsatile
SNP
SNP
pH -sta t
0
A lpha-sta t
0
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Study design
Clearly statistically significant effects were found in this study using a 
relatively small population. A larger population might have resulted in other 
significant findings and it would certainly have enabled narrower confidence 
limits to have been calculated. However, if significant effects can be found w ith 
a small population then it is ethically unsound to study a larger number of 
patients. To obtain the same degree of precision using a non-factoria l design 
would have required much larger numbers and detection of interaction would 
not have been possible 138,139
Metabolism
F/owrate. The change in system ic oxygen uptake induced by alternating flow  
rate must have been mediated by either changes in tissue oxygen extraction, 
distribution of blood flow  through the microcirculation or a com bination of both 
factors. Lack of variation in oxygen extraction implies that the change in 
systemic oxygen uptake was purely related to the distribution of blood flow  
through the tissues. Therefore, it would appear that system ic oxygen uptake was 
decreased at 1.5 L .m in V ir r 2 due to  impaired tissue perfusion. This conclusion is 
supported by the associated changes in haemodynamic variables as w e ll as by 
the similar findings of Harris, Seelye and Squire 51. In contrast to  the present 
study, Fox and colleagues 60 found an increase in oxygen extraction to  be 
associated w ith  reduction in flow  rate during cardiopulmonary bypass using 
profound hypothermia. However, their use of extremely low  flow  rates (down to 
0.25 L.m in-1.m 2) may account for this difference in findings. Flow rates used in 
the present study were chosen to  lie within the higher range of com m only 
employed low  rates of flow . As the present study exam ined only tw o  flow  rates, 
it cannot determ ine the rate of flow  at which system ic oxygen uptake might 
plateau though the findings clearly show that system ic oxygen uptake is less 
than maximal at 1.5 L.m in-1.m-2. In contrast, both Hickey and Hoar 6S and Fox
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and co-w orkers 60 found that during moderate and profound hypotherm ia 
respectively, system ic oxygen uptake reached a plateau at 1.2 L .m in 1. mr2. As 
discussed in Chapter 2, these findings may have been influenced by choice of 
study design and statistical analysis. The findings from the present study 
indicate that system ic oxygen uptake was not maintained and therefore, the 
physiological rationale for using low flow  rates is flawed.
With the decrease in system ic oxygen uptake found at the lower flo w  rate, 
a resultant increase in anaerobic metabolism would be expected. However, no 
significant increases in base excess or lactate concentration were found at the 
lower com pared to  the higher flow  rate. These apparently conflic ting results 
have been found in the past by Harris, Seelye and Barratt-Boyes 40. They 
postulated that anaerobic metabolism occurs at low  flow  rates but does not 
register on a system ic scale because there is little or no perfusion in the areas 
where it is occurring. Thus, although there was no measured increase in 
anaerobic m etabolism  at the lower flow  rate in the present study, its occurrence 
may have been concealed.
In contrast to  earlier studies 5 48, the present study found an overall 
reduction in lactate concentration w ith  stage and this is perhaps accounted for 
by metabolism or redistribution of lactate present in the crystalloid prim e during 
the course of cardiopulmonary bypass.
Flow character. Unlike many previous studies 43-45.69.7o.72j this study failed to 
detect any m etabolic superiority of pulsatile over nonpulsatile perfusion. The 
most fundam enta l exp lana tion  may lie in the device used to  genera te  pulsation  
as the Stockert pump used in the present study has been found by W right to  
produce less pu lsatile  pow e r than others ' c‘ . Thus, flow' character's  fa ilure  to  
influence m etabolism  in the present study could simply be the result o f fa iling to 
generate sufficient pulsatile power. Another factor that may account for the 
different findings is the use of hypothermia in the present study as this was not 
employed in m ost early studies. In addition this study, unlike the m ajority of 
previous studies, not only continuously quantified the pulse pressure but also
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demonstrated it to  be significantly different between nonpulsatile and pulsatile 
perfusion 12. However, pulse pressure alone may not be a good index of 
pulsatility 152. Moreover, during nonpulsatile perfusion in the present study, there 
was a sizeable mean pulse pressure which is an artefact of roller pumps. 
Therefore, this study may be criticised for comparing tw o  form s of pulsatile flow  
character rather than true nonpulsatile and pulsatile perfusion 12. For these 
reasons, this study cannot exclude the possibility that there are m etabolic 
differences be tw een truly nonpulsatile  and pulsatile flo w  characters. 
Nonetheless, nonpulsatile and pulsatile perfusion are com m only produced in the 
manner used in this study during clinical practice and therefore, the present 
comparison has validity.
Although the m ajority of previous studies have found pulsatile to  have 
metabolic superiority to  nonpulsatile perfusion 12, this study is not isolated in its 
failure to dem onstrate that flow  character has any influence on m etabolic 
variables 4 7 . 7 1 , 7 2 . As discussed in Chapter 2 , other negative findings have been 
dismissed on the grounds that high flow  rates were em ployed 12. However, both 
flow rates exam ined in the present study are w ithin the low range and no 
significant differences between nonpulsatile and nonpulsatile perfusion w ere 
found. This would imply that differences in flow  character are not m ore apparent 
at low flow  rates.
Acid-base management. As discussed in Chapter 4, neither true alpha nor 
pH-stat conditions w ere  obtained despite using inline blood gas m onitoring. 
Thus, this study cannot exclude the premisethat differences in system ic oxygen 
uptake may exist betw een pH and alpha-stat acid-base management. However, 
a reasonably large and significant change in arterial pH was induced and this 
should give an indication of the possible differences between the tw o  form s of 
acid-base management. Nonetheless, under the conditions of this study, the 
lack of a significant relationship between arterial pH and system ic oxygen 
uptake indicates that the choice of acid-base management has little  influence 
on systemic metabolism .
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The strongly significant relationship between arterial pH and base excess, 
although very small in magnitude, could imply that lower pH produces m ore 
metabolic acidosis. It is more likely that these changes result from inducing
acute changes in aderial carbon dioxide tension as this is known tn cause a fall 
in base excess in dogs and can be mistakenly interpreted as m etabolic 
acidosis 153.
Haemodynamics
Flow rate. The increase in peripheral vascular resistance w ith  reduction in flow  
rate in this study confirm s the recognised inverse relationship between these 
two variables 34'123. This relationship may possibly be explained by a passive 
capillary mechanism 34 123 because capillaries behave as Starling resistors 
(Figure 12). For flow  to  occur in a capillary, the pressure at the arterial end must 
exceed that at the venous end which in turn must exceed the closing pressure 
exerted by the surrounding tissue. Thus, unlike a rigid tube in which flow  
increases linearly w ith pressure (Figure 13a), flow  com m ences in a capillary at 
the critical c losing pressure then increases exponentia lly w ith increasing 
pressure (Figure 13b) 154. Therefore, the increase in peripheral vascular 
resistance at the lower com pared to the higher flow  rate in the present study 
could represent a proliferation of capillaries in which the critical closing pressure 
was no longer exceeded. Thus, the increase in peripheral vascular resistance 
with decreasing flow  rate would indicate impaired tissue perfusion. Indeed, this 
conclusion is supported by the significant correlation between within patient 
changes in peripheral vascular resistance and system ic oxygen uptakes that 
resulted from alternation o f flow  rate.
Flow character. As w ith  m etabolism  and unlike many previous studies 43- 
45,67-70,106  ^ no haem odynam ic superiority was found to be associated w ith  a 
pulsatile com pared to  a nonpulsatile flow  character. Possible explanations for 
these results are sim ilar to  those stated previously concerning the m etabolic 
findings. Furthermore, recent work by Sohma and colleagues using a canine
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hind limb model concluded that peripheral vascular resistance is a function of 
both flow  rate and character 155. The present work, as w ith  that of Sohma and 
colleagues, confirm s the supposition made in Chapter 2 that the findings from 
studies com paring pulsatile and nonpulsatile perfusion are invalid unless the flow  
rate was contro lled in both groups. As w ith  the m etabolic findings, the present 
study is not isolated in its failure to dem onstrate any haemodynamic superiority 
of pulsatile over nonpulsatile perfusion 8 .4 7 . 7 1 , 7 2 .1 2 4
As no significant differences w ere found between nonpulsatile and 
pulsatile perfusion, and also because of the great variability in pulse pressure 
found during pulsatile perfusion, a nonpulsatile flow  character was used in all 
further studies.
Acid-base management. Arterial pH had little or no effect on mean arterial 
pressure during Period 1 but, by Period 2 mean arterial pressure was higher w ith 
alpha than pH -sta t control and this difference was maintained in Period 3. 
Increased mean arterial pressure at lower carbon dioxide tension and higher pH 
and vice versa would fit w ith  the known vasoactive effects of carbon dioxide 
and hydrogen ions in the intact cardiovascular system at normotherm ia 156, 
However, com mensurate significant changes in peripheral vascular resistance 
would have been expected and these did not occur. It is possible that this study 
simply failed to  detect this change, due to  the increased variability introduced by 
the inclusion of central venous pressure data in the calculated peripheral 
vascular resistance. The lack of difference in mean arterial pressure during 
Period 1 is more difficult to  explain, although it may be due to  initial vasom otor 
paralysis after which tone and reactivity to  carbon dioxide tension and hydrogen 
ion concentration is progressively regained.
Although the findings of the present study are inconclusive as to  the 
advantages of one form of acid-base m anagement over the other, as the 
present w e igh t of evidence is in favour of alpha-stat acid-base management 
126'157, this form  of pH control was used in all further studies.
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Progressive vasoconstriction. During the course of cardiopulmonary bypass 
there were progressive increases in mean arterial pressure and peripheral 
vascular resistance which, as discussed in Chapter 2, are well recognised 
phenomena. The inexorable increase in peripheral vascular resistance, as with 
the rise which occurred with reduction in flow rate, might indicate impairment of 
tissue perfusion. However, systemic oxygen uptake did not significantly change 
during the course of the study and in fact, there was a small but significant 
decrease in lactate concentration. It is most likely that the disparity in metabolic 
effects reflect differing mechanisms causing the increase in peripheral vascular 
resistance. Unlike the passive mechanism, argued previously for the effects of 
flow rate on peripheral vascular resistance, the progressive increase in 
peripheral vascular resistance during cardiopulmonary bypass may result from 
active vasoconstriction of metarterioles and pre-capillary sphincters 123. If the 
rise in peripheral vascular resistance is due to an increase in vasomotor tone, 
rather than capillary closure, tissue metabolism will be unimpaired. This 
difference in the mechanism affecting peripheral vascular resistance would 
explain why Evans and colleagues, using sodium nitroprusside, were unable, 
despite producing a marked decrease in peripheral vascular resistance, to detect 
any change in systemic oxygen uptake 46 as sodium nitroprusside acts by 
reducing vasomotor tone.
One of the suggested haemodynamic advantages of pulsatile over 
nonpulsatile perfusion is the prevention of progressive vasoconstriction 12. In the 
present study, interaction between flow character and stage during 
cardiopulmonary bypass was specifically examined for, yet none was found. 
Pulsatile perfusion was not found to ameliorate the increase in peripheral 
vascular resistance. Other workers have also been unable to find any difference 
in the rate of vasoconstriction between pulsatile and nonpulsatile perfusion 
47 72 124. It is difficult to resolve these contrary haemodynamic findings unless 
there are important differences in anaesthetic or cardiopulmonary bypass 
techniques between those studies that have found pulsatile perfusion to 
ameliorate the ongoing vasoconstriction and those which have not.
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Haematocrit and reservoir vo/ume. A possible explanation for the interaction 
between flow  rate and stage during cardiopulmonary bypass on haematocrit 
might be ongoing haemorrhage. By Period 3, blood loss may have reached a 
sufficient am ount in som e patients, such that hypovolaemia would be apparent if 
a high flow  rate was used, but would be disguised if a low  flo w  rate was 
employed. Thus, low  reservoir volumes would occur more often w ith  a high flow  
rate and w ould  likely be treated w ith  lactated Ringer’s solution to  produce 
haemodilution, a series of events which would be less likely to  occur w ith  a low 
flow rate. Indeed, the lower mean reservoir volume at the high flow  rate during 
Periods 1 and 2 fo llow ed  by a higher volume in Period 3 would support this 
supposition. Nonetheless, it is unlikely that this effect of interaction between 
flow rate and stage on haematocrit would have any im portant e ffect on 
haemodynamic variables as it was of such small magnitude.
In conclusion, this study has found that flow  rate had im portant e ffects on 
both system ic oxygen uptake and peripheral vascular resistance. In contrast, the 
choice of flow  character and acid-base management had no significant effect 
on either system ic oxygen uptake or peripheral vascular resistance.
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HAEM ODYNAM IC AND METABOLIC EFFECTS OF 
ISOFLURANE DURING HYPOTHERM IC  
CARDIOPULMONARY BYPASS
METHODS
Study design
Twenty patients scheduled for elective heart valve or coronary artery 
surgery w ere  allocated randomly into tw o equal groups in an open, crossover 
study. During cardiopulmonary bypass, patients in Group I were given isoflurane 
from the beginning until the end of Period 1 when it was discontinued. In Group 
II, patients w ere  given no isoflurane during cardiopulmonary bypass until the end 
of Period 1 and this was then continued until the end of cardiopulmonary 
bypass. In both groups, the vaporiser was set at 5% for 5 m inutes then reduced 
to 2% until discontinued.
Anaesthesia
Patients w ere premedicated w ith lorazepam 2-4  mg orally on the night 
prior to surgery and temazepam 20-50 mg orally approxim ate ly one hour before 
surgery. Anaesthesia was induced with fentanyl 5 ug.kg-1 and a sleep dose of 
midazolam IV. Neuromuscular blockade was obtained w ith  vecuronium 0.15 
mg.kg^1 IV and then maintained with an infusion at 2.5 ug.kg ^.min-1. The trachea 
was intubated and the lungs ventilated w ith nitrous oxide and oxygen (50/50% ) 
to achieve eucapnoea Anaesthesia was m aintained throughout the procedure 
with an infusion of fentanyl 0.1 ug.kg-1.min-1 IV and was supplem ented, before 
and after cardiopulm onary bypass, with isoflurane.
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Statistical analysis
All data were analysed by regression of w ithin patient changes in 
measured variables between Periods 1 and 2 upon the corresponding changes 
in blood isoflurane concentration. Data identified as being of most importance 
(system ic oxygen uptake, lactate concentration, base excess, mean arterial and 
central venous pressures and peripheral vascular resistance) w ere subjected to 
more rigorous examination with multiple regression analysis and factorial 
analysis of variance. The level of statistical significance was taken as 5% and 
Bonferonni’s correction for multiple comparisons applied. Probability values are 
presented uncorrected.
RESULTS
Patient details
Patients demographic details and relevant durations are presented in 
Tables XI. Six of the patients underwent heart valve replacem ents and 14 of 
them had coronary artery bypass surgery.
Thermostatic control
G ood temperature control was achieved as there was only one patient 
period in which the 95% confidence interval for the repeated m easurements of 
nasopharyngeal temperature fell outw ith the prescribed range (27-29°C) and the 
mean in that instance was 26.8°C.
Acid-base management
Over all, similar values of arterial pH were found during periods when 
isoflurane was and was not administered (Table XII). No significant correlation 
was found between changes in arterial pH or carbon d ioxide tension and 
changes in blood isoflurane concentration (Table XIII).
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Table XI. Dem ographic details and durations.
Mean Standard deviation
Sex (F/M) 6/14 -
Age (yr) 57 9.8
Weight (kg) 75 11.5
Height (m) 1.68 0.11
Surface area (m 2) 1.84 0.21
Cardiopulmonary bypass (min) 86 16
Cross clamp (min) 59 12
Table XII. Mean variables (standard deviation) during Periods when isoflurane 
was (Isoflurane) and was not (No isoflurane) administered (n = 20).
Variable No isoflurane Isoflurane
Isoflurane (ug .m N ) 7.1 (7.1) 54.3 (20.7)
Arterial pH 7.38 (0.03) 7.38 (0.03)
PaC02 (m m Hg) 41 (5.2) 41 (4.4)
C a02 (m l.L -1) 126 (22) 130 (22)
C v02 (m l.L -1) 95 (16) 97 (17)
C a -v0 2 (m l.L -1) 31 (10) 33 (10)
V 02 (m l.m in -1.m-2) 49 (18) 52 (15)
Sa02 (%) 98 (1.0) 98 (1.1)
Sv02 (%) 82 (5.4) 83 (4.5)
Pa02 (m m Hg) 428 (176) 421 (167)
Pv02 (m m Hg) 48 (5.3) 50 (5.5)
H b a fg .L -1) 84 (13.7) 84 (12.7)
H b v(g .L -1) 84 (13) 84 (14)
Lactate (m m l.L -1) 2.3 (0..77) 2.4 (0.8)
Base Excess 0.8 (1.8) 0.2 (1.7)
Haematocrit (%) 25 (4.1) 26 (3.8)
MAP (m m Hg) 57 (13.1) 43 (8.2)
PVR (dynes.s.cm -5) 1564 (396) 1159 (329)
CVP (m m Hg) 0.1 (5.9) 0.5 (5.5)
Reservoir level (ml) 1402 (846) 1245 (543)
Table XIII . Changes in m etabolic variables between Periods 1 and 2 regressed
upon corresponding 
y = a + bx.
changes in blood isoflurane concentration (ug.m M )
Variable a b 95% CL of b r P
Arterial pH -0.005 0 -2.44 . 10-4, 
2.44 . 10-4
0.157 0.500
PaC02 (mmHg) 0.752 -0.004 -3.94 . 10-2- 
3.86 . 10-2
0.055 0.825
Ca02 (ml.L-1) -3.34 0.07 -3.55 . 10-2, 
1.75 . 10"1
0.312 0.164
Cv02 (ml.L-1) -2.45 0.02 -8.013 . 10-2, 
1.201 . 10“1
0.111 0.636
Ca-v02 (ml.L-1) -0.041 -1.45 3.807 . 10-3,
9.807 . 10-3
0.189 0.414
V02 (ml.min-1.m-2) -6.89 0.793 -0.248,
1.834
0.124 0.596
Sa02 (%) -1.493 0.007 8.74 .10-5. 
1.39 . 10-2
0.424 0.048
Sv02 (%) 28.5 0.042 4.00 . 10-3,
8.00 . 10-2
0.476 0.022
Pa02 (mmHg) -2.46 2.496 2.37 . 10-1, 
4.755
0.480 0.021
Pv02 (mmHg) 0.007 0.035 -1,2 . 10-2, 
8.2 . 10"2
0.352 0.111
Hba (g.L-1) -0.147 0.001 -3.85 . 10-3, 
5.85 . 10-3
0.067 0.776
Hbv (g.L-1) -6.527 0.408 -8.2 . 10-3, 
-3.8 . 10-3
0.049 0.834
Lactate (mmol.L-1) -0.219 -0.006 -0.021. 
6.72 . 10-4
0.507 0.013
Base Excess -0.83 -0.010 -0.021,
6.77.10"4
-0.414 0.054
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Isoflurane concentrations
A large interpatient variability in blood isoflurane concentration was found 
though a steady state was achieved during the study periods (Figure 14 and 
Table XII).
Metabolic variables
Average values of metabolic variables during periods when isoflurane was 
and was not administered are presented in Table XII. No significant correlation 
between changes in blood isoflurane concentration and changes in system ic 
oxygen uptake from Periods 1 to  2 was found (Figure 15 and Table XIII). 
Statistical modelling of the system ic oxygen uptake data found no sensitivity to  
isoflurane nor any effect due to period of study during cardiopulmonary bypass.
No significant correlations w ere found between change in blood isoflurane 
concentration and changes in arterial and venous oxygen content, venous 
oxygen tension or base excess (Table XIII). On individual analyses of each 
variable, significant correlations were found between changes in blood 
isoflurane concentration and changes in arterial and venous haemoglobin 
oxygen saturation, venous oxygen tension and lactate concentration (Table XIII). 
However, after application of Bonferonni’s correction for repeated comparisons, 
all these findings were nonsignificant.
M odelling of the base excess and lactate concentration data found no 
sensitivity to  isoflurane concentration but stage had a significant effect. Base 
excess decreased on average by 0.47 (95%CL 0.09, 0.86) from Period 1 to  2 
and lactate concentration decreased by 0.30 (95%CL 0.10, 0.51) m m ol.L-1 over 
the same time.
Haemodynamic variables
Average mean arterial pressures, peripheral vascular resistances, central 
venous pressures and reservoir levels during periods of no isoflurane and 
isoflurane administration are presented in Table XIV. Changes in mean arterial
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Figure 15. Relationship between changes in blood isoflurane concentration 
between Periods 1 and 2 and corresponding changes in system ic oxygen 
uptake (V 0 2). Continuous lines represent changes in Group 1 and dashed 
lines changes in Group 11.
Table XIV. Changes in haemodynamic variables between Periods 1 and 2
regressed upon corresponding changes in blood isoflurane concentration.
Variable a b 95% CL of b r P
Haematocrit (%) -5.75 2.5 -7.98,
13.01
0.123 0.598
MAP (mmHg) -8.02 -0.254 -0.302,
-0.206
-0.777 0.001
CVP (mmHg) -0.83 -0.003 -8.379 .10-3 
1.24.10-2
0.043 0.855
PVR (dynes.s.crrr5) -212 -7.266 -10.16,
-4.38
-0.793 0.001
Reservoir level (ml) 265 -3.794 -8.66,
1.07
-0.375 0.867
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pressure and peripheral vascular resistance between Periods 1 and 2 were 
found, after application of Bonferonni's correction, to correlate significantly w ith 
the change in blood isoflurane concentration (Figures 16 and 17). M odelling of 
the mean arterial and peripheral vascular resistance data found there to  be 
significant main effects due to  isoflurane concentration and period of study 
during cardiopulmonary bypass. In addition, there was a significant interaction 
between isoflurane concentration and period. There was a difference in the 
haemodynamic response to  isoflurane according to the period of study. Mean 
arterial pressure decreased on average during Period 1 by 0.59 (95% CL 0.36, 
0.82) mmHg per 1 ug.m H increase in isoflurane whereas during Period 2, it 
decreased on average only by 0.03 (95%CL -0.17, 0.24) mmHg per 1 ug.mM 
increase in isoflurane. Similarly, peripheral vascular resistance decreased during 
Period 1 by 15.8 (95% CL 9.3, 22.4) dynes.s.cm-5 per 1 ug.m H increase in 
isoflurane whereas during Period 2, it decreased on average by 0.3 (95% CL 
-5.6, 6.3) dynes.s.cm-5 per 1 ug.m H.
No significant correlation was found between changes in central venous 
pressure, reservoir level or haematocrit and changes in isoflurane concentration 
(Table XIV). Modelling of the central venous pressure data found no sensitivity 
to isoflurane concentration or to  period of study.
Vasoactive drugs
In Period 1, m ore patients w ho received isoflurane compared to  those who 
did not, were given m ethoxam ine (Table XV). No m ethoxam ine was given in 
Period 2 in either group. One patient in Group 2 required sodium nitroprusside to 
control hypertension in both the first and second periods.
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Figure 16. Relationship between changes in blood isoflurane concentration 
between Periods 1 and 2 and corresponding changes in mean arterial 
pressure. Continuous lines represent changes in Group 1 and dashed lines 
changes in Group 11.
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Figure  17. Relationship between changes in blood isoflurane concentration 
between Periods 1 and 2 and corresponding changes in peripheral vascular 
resistance. Continuous lines represent changes in Group 1 and dashed lines 
changes in Group 11.
Table XV. Incidence of methoxamine administration (n = 10).
Group I Group II
(isoflurane/ no (no isoflurane/
isoflurane) isoflurane)
Period 1 7 2
Period 2 0 0
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DISCUSSION
The principal findings of this study are that change in blood isoflurane 
concentration had significant effects on mean arterial pressure and peripheral 
vascular resistance whereas it had no significant action on system ic oxygen 
uptake.
Isoflurane concentration
A large interpatient variability in blood concentration of isoflurane was 
found despite using a standardised regim e for isoflurane administration. The 
pharmacokinetics of isoflurane, when delivered into the the oxygenator during 
hypothermic cardiopulmonary bypass, are poorly understood as they have not 
been rigorously studied. Haemodilution reduces the solubility of isoflurane 158 
whereas hypothermia increases it 159 but how these and other effects interact 
during hypothermic cardiopulmonary bypass is poorly understood. Loom is and 
colleagues examined the arterial concentrations of isoflurane that were required 
to produce electro-encephalographic burst suppression during cardiopulmonary 
bypass at 25°C and found similar levels and variablity to  the present study at a 
mean vaporiser setting of 2.2% 16°. As the pump flow  rate was constant during 
the present study, the variability is m ost likely accounted for by d ifferences in 
gas flow  rates to  the oxygenator. The gas flow  rate to  the oxygenator was 
altered, as required to  control the arterial pH and blood gases, from  less than 1 
L.min-1 to  over 5 L.m in-1. This manipulation w ill have caused considerable 
changes in the rate of isoflurane delivery. However, isoflurane has been found 
to decrease cerebral m etabolic rate during cardiopulmonary bypass w ith  
moderate hypothermia at lower vaporiser settings than the present study 161. 
Therefore, if there are sytem ic m etabolic effects from  isoflurane during 
hypothermic cardiopulmonary bypass then they should be detectable at the 
concentrations obtained in this study.
Because of the poorly understood pharmacokinetics, it is difficult to  relate 
directly any changes in variables induced by isoflurane during cardiopulmonary
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bypass to  those that occur in the intact cardiovascular system at normotherm ia. 
The actions of volatile anaesthetic agents are usually related to  the m inimal 
alveolar concentration which, under standard conditions, can be readily 
calculated from blood concentration. As the relevant solubility coeffic ients for 
isoflurane under the conditions of hypotherm ia and haemodilution are not 
available, it is not possible to determ ine the minimal alveolar concentration 
related to  the blood isoflurane concentrations found in the present study.
Metabolism
No relationship was found in the present study between isoflurane 
concentration and system ic oxygen uptake. In the intact cardiovascular system  
at normothermia, isoflurane decreases system ic oxygen uptake 9°-92 and sim ilar 
effects m ight be expected during cardiopulmonary bypass. A possible 
explanation for the failure of the present study to  detect any change in system ic 
oxygen uptake is that isoflurane did produce metabolic depression but this effect 
was counteracted by vasodilation which improved tissue oxygen uptake in areas 
otherwise hypoperfused. However, it is more likely that isoflurane did not have 
any direct system ic m etabolic e ffect in the blood concentrations obtained in this 
study as vasodilation in itself has not been found to  improve sytem ic oxygen 
uptake 46. Two important differences exist between this and previous studies 
which have found isoflurane to reduce system ic oxygen uptake. Hypotherm ia, 
which was used in this study, markedly decreases metabolism and this effect 
may be far greater than that of isoflurane. Thus, any metabolic e ffect may be 
too small to  detect w ith the present methods. Also, isoflurane may decrease 
systemic oxygen uptake in the intact cardiovascular system largely by 
decreasing cardiac output and not by direct m etabolic depression 91. If this is the 
case then isoflurane w ill not affect system ic oxygen uptake as the heart is 
isolated from  the circulation and the pump flow  rate was kept constant during 
cardiopulmonary bypass. If this is not the case, it is difficult to resolve the lack of 
systemic m etabolic effects found in the present study w ith the detectable
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cerebral m etabolic effects that have been found previously 161.
On the basis of the present study, there would appear to  be no system ic 
m etabo lic  advantage in the use of isoflurane during hypotherm ic 
card iopu lm onary bypass as it euner nas ,io  m etabolic effect under these 
conditions or the effects are too small to be clin ically useful. However, 
isoflurane may have a cerebral protective effect during cardiopulmonary bypass 
and this w ould  be an important indication for its use 161.
Haemodynamics
Undoubtedly, the high incidence of m ethoxam ine adm inistration during 
Period 1 in those patients who were given isoflurane only in Period 1 w ill have 
reduced the measured changes in their mean arterial pressures and peripheral 
vascular resistances. This high incidence of m ethoxam ine adm inistration reflects 
the strong interaction between isoflurane and stage of the study period during 
cardiopulmonary bypass. This interaction may be explained by isoflurane’s 
blunting e ffect on the progressive rise in noradrenaline that occurs during the 
course of cardiopulmonary bypass 162. Progressive vasoconstriction during 
cardiopulmonary bypass also accounts for the more marked changes in 
haemodynam ic variables in those patients who received isoflurane only in the 
first period and the less marked changes in those patients who w ere given 
isoflurane only in the second. In some patients who received isoflurane only in 
the second period, isoflurane did not produce vasodilation though it did 
am eriolate the ongoing vasoconstriction. For the same reason, som e of the 
increases in mean arterial pressure and peripheral vascular resistance in those 
patients w ho w ere given isoflurane only in Period 1 are accounted for by 
progressive vasoconstriction during the course of cardiopulmonary bypass.
The high incidence of hypotension, as indicated by the need for 
m ethoxam ine, is clinically important. Marked hypotension is dangerous as it may 
produce cerebral hypoperfusion and ischaemia 9. However, this hypotension is 
readily corrected by using vasoconstrictors or increasing the flow  rate until the
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condition resolves spontaneously as a result of ongo ing  vasoconstriction. 
Furthermore, isoflurane’s potential for hypotension must be balanced against the 
risk of hypertension if isoflurane is not used and that can result in catastrophic
aortic disruption at the cannulation s;te
The vasodilatory effects of isoflurane found in this study during the 
abnormal conditions of low flow , hypothermic cardiopulm onary bypass are 
consistent w ith the known actions of isoflurane in the intact cardiovascular 
system at norm otherm ia 90. The findings of this study im ply that isoflurane could 
be used as a vasodilator to  control systemic arterial pressure in a dose related 
manner during hypotherm ic cardiopulmonary bypass. Contro lling systemic 
arterial pressure w ith  isoflurane would be a more appropriate choice than other 
non-anaesthetic vasodilators as isoflurane would at least lessen the risk of 
awareness and at best obviate it.
In conclusion, isoflurane is a vasodilator and produces dose related change 
in mean arterial pressure during hypothermic cardiopulmonary bypass but has no 
significant m etabolic effects.
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CHAPTER 7
HAEMODYNAMIC AND METABOLIC EFFECTS OF 
A TRA C U RIUM  DURING  HYPOTHERMIC  
CARDIOPULMONARY BYPASS
METHODS
Study design
Twenty patients scheduled for elective coronary artery surgery w ere 
allocated randomly into tw o  equal groups. A parallel group study design was 
employed. Patients in the Control Group were given no atracurium during the 
study. In contrast, patients in the Atracurium Group received no atracurium until 
the end of Period 1 when they were given a bolus of atracurium 0.6 m g.kg-1 IV 
followed by an IV infusion at 0.7 ug.kg-1.m in-1. On com pletion of the study, 
patients in the Control Group were also given atracurium.
Anaesthesia
Patients were premedicated w ith  lorazepam 2-5  mg orally on the night 
prior to surgery and temazepam 20-50 mg orally approxim ately one hour before 
induction of anaesthesia. Anaesthesia was induced w ith  fentanyl 5 ug.kg-1 IV 
followed by a sleep dose of m idazolam IV. Ventilation was controlled and 
isoflurane was adm inistered in 100% oxygen until the systolic arterial pressure 
was reduced to  80% of the pre-induction value. A fter topical application of 
lignocaine 4% to  the pharynx and glottis, the trachea was intubated. In the event 
of difficulty w ith  tracheal intubation or opioid rigidity, suxamethonium was 
administered. Before and after cardiopulmonary bypass, the lungs w ere 
ventilated w ith  nitrous oxide and oxygen (50/50%) to  maintain eucapnoea. 
Anaesthesia was maintained throughout surgery w ith  an infusion of fentanyl
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0.1 ug.kg-1.m in-1 IV. This was supplemented w ith isoflurane before and after 
cardiopulmonary bypass. Throughout cardiopulmonary bypass, 1% isoflurane 
was adm in istered to maintain anaesthesia.
Statistical analysis
Data w e re  analysed by comparison of w ithin patient changes between 
Periods 1 and 2 in both the Control and Atracurium Groups using a paired 
Student’s t test. Comparison of between groups differences during Periods 1 
and 2 w ere  m ade using an unpaired Student’s t test. Bonfe ronn i’s correction for 
multiple com parisons was then applied. Results are presented in the tables in 
their uncorrected form.
RESULTS
Patient details
Dem ographic details and relevant durations are presented in Table XVI. 
There w ere  sim ilar distributions of anti-anginal drugs in both groups (Table XVII).
Thermostatic control
Tem perature control was excellent as all the 95% confidence lim its of the 
means for the repeated arterial and nasopharyngeal tem perature readings were 
within the prescribed limits (27-29°C; Table XVIII).
Acid-base managment
Arterial pH measurements by bench blood gas analysis found that 
alpha-stat ac id-base management was not always accurately achieved although 
there w ere  no significant differences in arterial pH either w ith in or between 
groups (Table XVIII). Similarly, there were no significant changes in arterial 
carbon d iox ide tension between or within groups (Table XVIII).
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Table XVI. Demographic details and durations [mean (standard deviation)].
Sex (F/M) 
Age (yr) 
Weight (kg) 
Height (m)
Control Group
0/ 10
52.3 (10.3)
78.3 (8.9) 
1.72 (0.067) 
1.91 (0.137)
85 (15)
55 (10)
Atracurium Group
2/ 8 
60.8 (7.8) 
74.7 (8.3)
1.68 (0.063) 
1.85 (0.135)
88 (18)
56 (15)
Surface area (m 2) 
Cardiopulmonary bypass (min) 
Cross clamp (m in)
Table XVII. Anti-anginal drugs.
Control Group Atracurium Group
Beta-adrenergic blockers 8 7
Nitrites 8 9
Calcium channel bockers 8 7
Table XVIII. Changes in arterial and nasopharyngeal temperatures (Ta, Tnp) 
arterial pH and P aC 02 in the Control and Atracurium Groups between Periods 1 
and 2 [mean (standard deviation)].
Variable Control Group Atracurium Group
Period 1 Period 2 d Period 1 Period 2 d
Ta (°C) 27.6 (0.2) 27.8 (0.3) -0.23 27.6 (0.3) 27.9 (0.3) -0.31
95% CL -0.35,-0.11 -0.38,-0.24
Tnp (°C) 28.4 (0.4) 28.3 (0.3) 0.14 28.3 (0.3) 28.2 (03) 0.2
95% CL 0.04, 0.24 -0.05, 0.45
Arterial pH 7.36 (0.04) 7.36 (0.05) 0.0 7.38 (0.03) 7.39 (0.05) -0.01
95% CL -0.01, 0.01 -0.03,0.00
PaC02 (mmHg) 43 (4.1) 43 (5.1) 0.0 42 (4.8) 42 (6.1) 0.35
95% CL -1.01, 1.01 -1.7, 2.4
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Metabolic variables
There w ere no significant differences in system ic oxygen uptake within 
either group between Periods 1 and 2 nor any between the groups (Figure 18). 
In both groups, there were small but nonsignificant increases in mean arterial 
blood oxygen content from Period 1 to  2. There w ere no significant differences 
in arterial blood oxygen content between groups (Table XIX) and no significant 
differences in m ixed venous oxygen content or oxygen extraction were 
found (Table XX).
No significant w ithin or between group changes in arterial haemoglobin 
oxygen saturation were found (Table XX). In both groups, there were no 
significant changes in arterial oxygen tension between Periods 1 and 2 (Table 
XX) nor were there any significant differences between the groups during Period
1. However, arterial oxygen tension was significantly higher in the Atracurium 
Group during Period 2. Between Periods 1 and 2, there w ere  small 
nonsignificant increases in the average m ixed venous blood oxygen tensions in 
both groups (Table XX). M ixed venous haem oglobin oxygen saturation did not 
change significantly between Periods 1 and 2 in either group (Table XX). Small 
increases in mean arterial haemoglobin concentration, that were nonsignificant, 
occurred between Periods 1 and 2 in both groups (Table XX). There were no 
significant changes in m ixed venous haem oglobin concentration in either group 
(Table XX).
There w ere  small decreases in mean base excess in both groups which 
were nonsignificant (Table XIX) and no significant between group differences in 
base excess w ere  found. From Period 1 to  2, there were small, nonsignificant 
decreases in mean lactate concentration in both groups (Table XIX) and there 
were no significant between group differences in lactate concentration.
Haemodynamic variables
In both the Control and Atracurium Groups, there were increases in the 
average mean arterial pressure from Periods 1 to  2 which were non-s ign ificant
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Figure 18. Changes in systemic oxygen uptake (V 0 2) between Periods 1
and 2 in the Control and Atracurium Groups,
Table XIX. Changes in arterial and m ixed venous blood oxygen contents, 
oxygen extraction, system ic oxygen uptake, base excess and lactate 
concentration in the Control and Atracurium Groups between Periods 1 and 2
[m ean (standard devia tion)].
Variable Control Group
d
Atracurium Group
Period 1 Period 2 Period 1 Period 2 d
Ca02 (ml.L-1) 127 (15) 130(16) -1.6 118 (17) 126 (18) -8.4
95% CL -5.2, 1.9 -16.2, -0.5
Cv02 (ml.L-1) 93 (15) 94 (13) -1.4 86 (18) 91 (17) -5.0
95% CL -6.5, 3.7 -11.3, 1.2
C a-v02 (m l.L '1) 37(9) 37(10) -0.5 31 (7) 34 (6) 0.5
95%CL -3.6, 2.6 -6.2, 5.2
V02 (m l.m irr1.rrr2) 59(14) 60(15) -1.0 50 (11) 54 (9) -4.2
95%CL -5.8, 3.9 -12.8, 4.4
Base Excess -1.3 (1.2) -1.2 (1.5) -0.05 -0.3 (1.5) 0.6 (1.6) -0.9
95% CL -0.91, 0.82 -1.6, -0.2
Lactate (mmol.L-1) 2.6 (0.6) 2.4 (0.5) 0.23 2.4 (0.6) 2.2 (0.6) 0.2
95% CL 0.02, 0.35 -0.0, 0.4
Table XX. Changes in arterial and venous oxygen saturations and tensions 
and haemoglobin concentration in the Control and Atracurium Groups between 
Periods 1 and 2 [mean (standard deviation)].
Variable Control Group Atracurium Group
Period 1 Period 2 d Period 1 Period 2 d
Sa02 (%) 98.0 (0.5) 97.5 (0.8) 0.4 98.2 (0.5) 98.2 (0.5) -3.6
95% CL 0,0.9 -6.2, 0.9
Sv02 (%) 76.3 (7.9) 78.0 (3.7) -1.6 78.8 (4.8) 82.3 (4.4) -3.4
95% CL -6.1, 2.8 -5 .6 ,-1 .1
Pa02 (mmHg) 345 (94) 360(148) -15 352 (121) 520 (248) -167
95% CL -77 ,47  -350 ,15
I -190 ,-130  I
Pv02 (mmHg) 44 (5.7) 45 (4.3) -1.5 44 (4.0) 48 (4.3) -3.4
95% CL -5.2, 2.2 -5 .0 ,-1 .8
Hba (g.L~1) 85.8 (11.2) -1.1 75.0 (6.7) 78.4 (8 1) 0
95% CL 84.6(10.7) -2.4,0.2 -0.3, 0.3
Hbv (g.L-1) 84.5 (10.7) 0.3 75.4 (10.8) 78.0 (8.1) -2.6
95% CL 84.8 (11.6) -2.9, 3.6 -7  7,2.5
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(Figure 19). There w ere no significant between group differences in mean 
arterial pressure. No significant differences in central venous pressure w ere 
found (Table XXI). Small, but nonsignificant, increases in mean peripheral 
vascular resistance occurred in both groups between Periods 1 and 2 (Figure 
20). There were no significant between group differences in peripheral vascular 
resistance.
There w ere no significant differences in central venous pressure, reservoir 
volumes or haematocrit (Table XXI).
Isoflurane concentration
Between Periods 1 and 2, there was a small decrease in mean blood 
isoflurane concentration in the Control Group whereas there was a small 
increase in the Atracurium Group (Table XXI). These changes w ere  not 
significant nor w ere there any significant differences in isoflurane concentration 
between groups.
Vasoactive drugs
Methoxam ine was adm inistered to  treat hypotension in one patient during 
Period 1 in the Control Group and in three patients during Period 1 and in one of 
the same patients during Period 2 in the Atracurium Group. No patient was given 
sodium nitroprusside.
DISCUSSION
The notable features of this study are the absence of any significant 
effects of atracurium on either haemodynamic variables or system ic oxygen 
uptake. A variety of factors must be considered as providing possible 
explanations for these findings. These factors w ill now  be considered 
individually to assess the like lihood  that they have influenced the results.
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Figure 19. Changes in mean arterial pressure between Periods 1 and 2 in
the Control and Atracurium Groups.
Table XXI. Changes in blood isoflurane concentration, haematocrit, mean 
arterial and central venous pressures, peripheral vascular resistance and 
reservoir level in the Control and Atracurium Groups between Periods 1 and 2 .
Variable Control Group Atracurium Group
Period 1 Period 2 d Period 1 Period 2 d
Isoflurane (ug.mh1) 35 (10.2) 32 (14.1) 2.8 26 (11.5) 31 (10.1) -4.8
95% CL -3.5, 9.1 -9.0,-0.5
Hct (%) 26 (3.4) 25 (3.9) 0.8 23 (3.7) 23 (3.0) -0.2
95% CL -1, 2.6 -2.6, 2.3
MAP (mmHg) 41 (9.2) 47 (9.5) -5.6 44 (6.1) 50 (7.4) -5.3
95% CL -11.2, -0.1 -9.0, -1.5
CVP (mmHg) 0.8 (5.1) 2.2 (5.4) -1.5 1.7 (4.4) 3.1 (5.5) -1.4
95% CL -4.2, 1.3 -3.4,0.6
PVR (dynes.s.cm-5) 1137 (305) 1180 (335) -43 1166 (194) 1280 (331) -114
95% CL -133, 47 -231, 4
Reservoir level (ml) 890 (277) 865 (286) 25 788 (203) 800 (234) -12
95% CL _ 124, 174 -135, 110
Peripheral vascular 
resistance
(dynes.s.cm ’5)
Control qroup
2000  - |
1000
Period 1 
(control)
Period 2  
(control)
Atracurium group
a  Peripheral 
vascular resistance 
( dynes.s.cm -5 ) 
r  250
Period 1 
(control)
Period 2  
(Atracurium]
- o
L -250
Figure 20. Changes in peripheral vascular resistance between Periods 1 and
2 in the Control and Atracurium Groups.
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Neuromuscular blockade
It could be argued that a com plete neuromuscular block may not have 
been produced during Period 2  in the Atracurium Group and therefore, the 
effects of atracurium would not be demonstrated. As no neuromuscular 
m onitoring was undertaken, it is not possible to  establish if this was the case. 
However, previous studies would suggest that the dose of atracurium em ployed 
was more than sufficient to  produce maximal neuromuscular blockade at 
norm otherm ia 131,132 Furthermore, hypotherm ia is know n to  cause 
neuromuscular blockade in itself and thereby, it reduces the required dosage 
requirements of neuromuscular blocking agents 130. For these reasons, 
inadequate neuromuscular blockade may be discounted as an explanation for 
the study’s findings.
Statistical analysis
Bonferonni’s correction for multiple comparisons, whilst reducing the risk 
of significant findings being due to chance, can overcom pensate when 
analysing large numbers of variables w ith the result that real changes com e to  
be discounted as nonsignificant. For this reason, the true probability of the 
statistical tests w ill lie between the uncorrected and corrected values. This point 
should be born in mind when considering the fo llow ing discussion.
Metabolism
The present study was unable to  confirm  the previous work of Underwood, 
Roth and Starr 85 and Harris, Seelye and Squire 51 which found that 
neuromuscular blocking agents reduced system ic oxygen uptake during 
cardiopulmonary bypass. These contrasting findings require consideration.
In the Atracurium Group, there was a small rise in arterial oxygen content 
between Periods 1 and 2  which, although nonsignificant after correction for 
multiple comparisons, may have resulted in an increased system ic oxygen 
delivery. This increase in oxygen delivery could have disguised a decrease in 
system ic oxvcien uptake induced bv atracurium. However, this is an unlikely
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explanation for not finding a significant decrease in system ic oxygen uptake 
associated w ith  the administration of atracurium as there was no concom itant 
increase in oxygen extraction by the tissues.
Another possible explanation for the difference in findings between the 
present and previous work may be the use of hypothermia. It is likely that 
neuromuscular blocking agents reduce system ic oxygen uptake at norm otherm ia 
by decreasing skeletal muscle tone and thereby, metabolism. If so, this effect 
may be dim inished or abolished at m oderate hypothermia as m etabolism  is 
already markedly reduced and muscle tone decreased. In contrast to 
Underwood, Roth and Starr’s study 85, no gross skeletal nor even any 
diaphragmatic m ovem ents were observed in the present study and this fact 
alone could account for the differences in findings.
Yet another explanation for not finding significant metabolic effects could 
lie in atracurium ’s absence of effect on haemodynam ic variables, as discussed 
be low . U n like  atracurium , tubocura rine  causes vaso d ila tio n  during 
cardiopulmonary bypass in humans 129. Therefore, the decrease in system ic 
oxygen uptake found by Underwood, Roth and S ta rr85 could have resulted from  
tubocurarine causing a maldistribution of b lood flow  through tissues, due to 
shunting, rather than direct metabolic depression.
Anaerobic metabolism
Small decreases in mean lactate concentration which occurred in both 
groups between Periods 1 and 2 w ere  nonsignificant after Bonferonni’s 
correction. A decrease in lactate concentration during the course of 
cardiopulmonary bypass would fit w ith the sim ilar findings in other studies of this
series
Haemodynamics
Tw o factors that should be borne in m ind when interpreting the changes in 
haemodynam ic variables are the adm inistration of m ethoxam ine and the
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increase in isoflurane concentration in the Atracurium Group between Periods 1 
and 2. Methoxamine administration, by causing vasoconstriction in Period 1, w ill 
have reduced the apparent magnitude of the increases in mean arterial pressure 
and peripheral vascular resistance that occurred. The increase in isoflurane 
concentration between Periods 1 and 2 in the Atracurium Group, which was not 
as marked in the Control Group, can only be ascribed to  chance as there was 
no difference in the method of isoflurane adm inistration between the tw o  
groups. This increase in isoflurane concentration in the Atracurium Group 
between Periods 1 and 2, although small, may have reduced the magnitude of 
the rise in mean arterial pressure and peripheral vascular resistance. Thus, the 
measured increases of these variables may have been underestimated.
In both groups, there were increases of sim ilar magnitude in mean arterial 
pressure between Periods 1 and 2 although these increases were nonsignificant 
fo llow ing  correction for multiple comparisons. A progressive rise in mean arterial 
pressure is a well recognised phenomenon of cardiopulmonary bypass and has 
been found previously in this project. It is therefore likely that the increase was 
true and the nonsignificant result is due to  overcom pensation by Bonferonni’s 
correction.
Although there were small mean increases in peripheral vascular resistance 
in both groups, they were not significant even before application of Bonferroni’s 
correction. The most likely explanation for these contradictory findings, relative 
to  mean arterial pressure, is that the study failed to  detect a true increase in 
peripheral vascular resistance. Increased variability introduced into the calculated 
peripheral vascular resistance by the central venous pressure data, which were 
highly variable, could indeed account for these findings.
From the findings of the present study, atracurium would appear to  have 
little  or no e ffec t on haem odynam ic variab les during hypotherm ic 
cardiopulmonary bypass. In contrast, tubocurarine causes a drop in mean arterial 
pressure during cardiopulmonary bypass due to  vasodilation 129. This d ifference
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in effect is unsurprising as atracurium, unlike tubocurarine, is already noted for its 
minimal haemodynam ic effects in the intact cardiovascular system  at 
normothermia 93. The present findings indicate that atracurium, as opposed to  
tubocurarine, has the same minimal haemodynamic actions during hypotherm ic 
cardiopulmonary bypass as it does in the intact cardiovascular system  at 
normothermia. The likely explanation for these differences in actions is that 
atracurium, com pared to  tubocurarine 128, produces much smaller am ounts of 
histamine release and also, does not cause autonom ic ganglion blockade 93.
In conclusion, the administration of atracurium during hypotherm ic 
cardiopulmonary bypass had no significant effects on haemodynam ic and 
metabolic variables.
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HAEMODYNAMIC AND METABOLIC EFFECTS OF 
A LFEN TA N IL D U RING  CARDIOPULMONARY BYPASS
METHODS 
Study design
Twenty patients scheduled for elective coronary artery surgery w ere  
studied. The study was planned to have an open crossover design. Patients 
were randomly a llocated into tw o  equal groups of ten. After achieving stable 
hypothermic cardiopulmonary bypass, patients in Group I underwent a control 
period (Period 1). They were then given alfentanil as a 50 ug.kg-1 bolus IV 
fo llow ed by an infusion at 1 ug.kg 1,min-1 and a second 10 minute study period 
performed (Period 2). A t the beginning of Period 1, Group II patients w ere given 
alfentanil 50 ug.kg-1 as an IV bolus fo llowed by an infusion at 1 ug.kg-1.m in-1. 
The infusion was discontinued at the end of Period 1 and a bolus of naloxone 
0.4 mg IV was given just before the start of Period 2. Haem odynam ic 
measurements w ere  recorded during and blood sampling perform ed at the ends 
of Periods 1 and 2 in both groups according to  the methods outlined in Chapters 
3 and 4. At the end of Period 2, the study was term inated in both groups and the 
alfentanil infusion was continued in Group I and recom menced in Group II.
Anaesthesia
Patients w ere prem edicated with lorazepam 2-5 mg orallv on the night 
prior to  surgery and om nopon 10-20 mg and hyoscine 0.2-0.4 mg IM 
approximately one hour pre-operatively. Anaesthesia was induced w ith  a sleep 
dose of m idazolam IV and neuromuscular blockade was then obtained w ith  
atracurium 0.6 mg.kg 1 IV. Ventilation was controlled and isoflurane adm inistered
92
Chapter 8 Alfentanil
until the systolic arterial pressure was reduced by 10-20% of preoperative value 
before tracheal intubation. Neuromuscular blockade was maintained throughout 
the procedure w ith an IV infusion of atracurium 0.7 ug.kg-1.min-1. Prior to 
cardiopulmonary bypass, the lungs were ventila ted w ith  nitrous oxide and 
oxygen (50/50%) to  achieve eucapnoea and anaesthesia was supplemented 
w ith  isoflurane. During cardiopulmonary bypass, anaesthesia was continued w ith 
isoflurane 1% vaporised into the gas supply to  the oxygenator.
Statistical analysis
The study was planned as an open crossover design. However, 
exam ination of the data found that there was a strong interaction between 
stage of the study period during cardiopulmonary bypass and alfentanil 
adm inistration on the haemodynamic data. Because of this interaction, the study 
was treated as a parallel group comparison. Data w ere  analysed using S tudent’s 
t test (paired and unpaired as appropriate) and Bonferonni’s correction for 
multiple comparisons was then applied.
RESULTS 
Patient details
Demographic details and relevant durations are presented in Table XXII. All 
patients were receiving one or more anti-anginal therapies (Table XXIII).
Thermostatic control
Good temperature control was achieved (Table XXIV).
Acid-base management
There were no significant differences in arterial pH or carbon dioxide 
tension either between Groups or within Groups from Period 1 to 2 (Table XXIV).
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Table XXII. Demographic details and durations [mean (standard deviation)].
Group I Group II
Sex (F/M) 1/9 2/8
Age (yr) 55 (4.6) 54 (9.8)
Weight (kg) 80 (10.2) 77 (8.4)
Height (m) 1.72 (0.08) 1.72 (0.09)
Surface area (m 2) 1.91 (017) 1.88 (0.16)
Cardiopulmonary bypass (min) 90 (17) 79 (15)
Cross clamp (min) 52 (10) 47(11)
Table XXIII. Anti-anginal drugs.
Group I Group II
Beta-adrenergic blockers 7 8
Nitrites 7 6
Calcium channel bockers 6 8
Table XXIV. Changes in arterial and nasopharyngeal temperatures (Ta, Tnp), 
arterial pH and P aC 02 in Groups I and II between Periods 1 and 2 [mean 
(standard deviation)].
Variable Group I Group II
Period 1 Period 2 d Period 1 Period 2 d
Ta (°C) 27.4 (0.3) 27.7 (0.2) -0.28 27. 6 (0.5) 27.8 (0.2) -0.15
95% CL -0.52, -0.05 -0.43, 0.14
Tnp (°C) 28.7 (0.3) 28.3 (0.4) 0.42 28.4 (0.3) 28.4 (0.3) 0.04
95% CL 0.13, 0.72 -00.6, 0.15
Arterial pH 7.41 (0.06) 7.44 (0.06) -0.03 7.38 (0.05) 7.37 (0.05) 0.01
95% CL -0.08, 0.01 0.00, 0.03
PaC02 (mmHg) 39 (5.7) 38 (6.0) 0.9 44 (5.7) 44 (6.3) -0 .6
95% CL -0.6, 2.5 -2.1, 0.9
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Metabolic variables
There w ere  no significant differences in system ic oxygen uptake between 
the groups nor w ithin the groups between Periods 1 and 2 (Figure 21). With the 
exception of arterial oxygen tension, there were no significant differences in 
oxygen variables between or within groups (Table XXV and XXVI). W ithin patient 
arterial oxygen tension did not change significantly between Periods 1 and 2 in 
either group. However, arterial oxygen tension was significantly higher in Group 
I during Period 2.
Before application of Bonferonni’s correction, there was a small but 
significant decrease in lactate concentration between Periods 1 and 2 in Group I 
which did not occur in Group II (Table XXV). However after correction, this 
change was nonsignificant. There were very small mean decreases in base 
excess in both groups (Table XXV) but again these w ere nonsignificant after 
application of Bonferonni’s correction.
Haemodynamic variables
Haem odynam ic data for one patient in Group I w ere lost due to  an 
operator error when saving the data to  disc. In Group I, mean arterial pressure 
and peripheral vascular resistance did not change significantly from  Period 1 to  2 
whereas they increased significantly in Group II between the tw o  periods 
(Figures 22 and 23). Central venous pressure, reservoir volum es and haematocrit 
w ere not significantly different between the groups nor w ith in the groups 
between Periods 1 and 2 (Table XXVII).
Isoflurane concentration.
No significant within patient changes in isoflurane concentration were 
found betw een Periods 1 and 2 in either Group (Table XVII). The mean isoflurane 
concentration was higher in Group I than Group II in both Periods but the 
differences w ere marginally nonsignificant after application of Bonferonni’s 
correction.
94
V ° 2
Aifentari ii  g roup
60
40
20
Period  1 Pe r iod  2 
(A l fentani l )  ( N a lo x o n e ;
N a l o x o n e  g r o u p
a  V o 2 
( m l .m in - ln r
d
( 0 
-10 
-20
P e r io d  1 
( c o n t ro l )
P e r io d  2 
'A l f en ta n i l
Figure  21. Changes in systemic oxygen uptake (V 0 2) between Periods 1 and
2 in Group I (Alfentanil) and Group II (Naloxone)
Table XXV. Changes in arterial and m ixed venous b lood oxygen contents, 
oxygen extraction, system ic oxygen uptake, base excess and lactate 
concentration in Groups I and II between Periods 1 and 2 [m ean (standard 
deviation)].
Variable Group I Group II
Period 1 Period 2 d Period 1 Period 2 d
C a02 (ml.L-1) 137 (14) 136 (14) 1.1 132 (13) 137 (14) -4.8
95% CL -1.7, 3.9 -10.8, 1.1
C v02 (ml.L-1) 103 (13) 103 (14) 0.4 100 (8) 103 (12) -2.6
95% CL -4.3, 5.2 -6.8, 1.6
C a -v0 2 (ml.L-1) 34 (6) 33 (9) 1.4 32 (8) 34 (4) 2.2
95%CL -3.0, 5.8 -6.4, 2.1
V 02 (ml.min-1,n r2) 54 (10) 52 (15) 2.5 51 (12) 55 (6) -3.33
95%CL -4.8, 9.7 -10.2, .3.6
Base Excess 0.4 (2.4) 0.1 (2.7) 0.3 0.8 (1.6) 0.6 (1.4) 0.4
95% CL -0.4, 1 0, 0.7
Lactate (m m ol.L '1) 2.5 (0.4) 2.4 (0.4) 0.17 2.3 (1.0) 2.2 (1.0) 0.05
95% CL 0.06, 0.28 -0.06, 0.16
Table XXVI. Changes in arterial and m ixed venous oxygen saturations and 
tensions and haemoglobin concentration in Groups I and II between Periods 1 
and 2 [mean (standard deviation)].
Variable Group I Group II
Period 1 Period 2 d Period 1 Period 2
Sa02 (%)
95% CL 
Sv02 (%)
95% CL 
Pa02 (mmHg) 
95% CL 
Pv02 (mmHg) 
95% CL 
Hba (g.L-1) 
95% CL 
Hbv ( g .L 1) 
95% CL
98 (.2) 98 (1.6) 0.5 98 (0.7) 98 (1.0) 0.2
-0.6, 1.5 -0.1, 0.5
82 (4.4) 84 (3) -1.8 81 (4.7) 82 (4.8) -0.6
-4.1, 0.4 -2.7, 1.5
351 (139) 341 (140) 10 262 (153) 258 (139) 15
-63. 83 -25, 35
66, 101 I
46 (3.8) 46 (3.8) -0.5 47 (5.8) 47 (5.9) -0 .5
-2.8, 1.9 -1.9, 1.0
89 (11.2) 89 (11) -0.1 87 (9) 89 (7) -2.2
-1 4 ,1 .2  -4 .5 ,0
89 (11.2) 89(11) -0.4 87 (8) 89 (7) -2.1
-1.8, 1.0 -4 .2 ,0
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Table XXVII. Changes in blood isoflurane concentration, haematocrit, mean 
arterial and central venous pressures, peripheral vascular resistance and 
reservoir level in Groups I and II between Periods 1 and 2 [mean (standard 
deviation)].
Variable Group I Group II
Period 1 Period 2 d Period 1 Period 2 d
Isoflurane (ug.ml-') 33 (10) 33 (11) 0.1
3, 21
21 (7) 24 (9) -2.8
95% CL
l
-4.2, 4.4 
4, 14
-7.7., 2.2
Hct (%) 27 (2.4) 27 (2.5) -0.2 27 (3.6) 27 (3.6) -0.8
95% CL -1.2, 1.0 -1.9, 0.4
MAP (mmHg) 43 (7.6) 43 (6.6) 0.1 48 (11.8) 63 (13) -14.2
95% CL
,
-2.6, 2.9 
-27, --12
-19.6, -8 .7
CVP (mmHg) 1.9 (2.6) 2.7 (3.2) -0.8 0.6 (3.2) 1.4 (3.9) -0.8
95% CL -1.4, -0.1 -2.7, 1.1
PVR (dynes.s.cm-5) 1070 (193) 1047 (172) 23 1254 (251) 1632 (350) -377
95% CL
I
-51, 97 
-621, - 547
-551, 204
Rervoir level (ml) 1660 (506) 1500 (612) 160 1380 (624) 1350 (535) 241
95% CL -132,452 -142, 202
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Vasoactive drugs
During Period 1, tw o  patients in each group were given m ethoxam ine. A 
further patient in Group I received methoxamine during Period 2. Tw o patients in 
Group II w ere  given sodium nitroprusside during Period 2.
DISCUSSION
The outstanding findings of this study are that mean arterial pressure and 
peripheral vascular resistance did not increase as expe c ted  during 
cardiopulm onary bypass when alfentanil was given, although they increased 
markedly when alfentanil was antagonised w ith naloxone. In contrast, there 
w ere no significant changes in metabolism.
Metabolism
Comparison of system ic oxygen uptake during Period 1 dem onstrated that 
there was no significant difference between the tw o  groups. Furthermore, 
neither adm inistration of alfentanil nor antagonism of alfentanil had any 
significant effect on system ic oxygen uptake. There is no previous w ork w ith  
which to  directly com pare these results. Tigerstedt and Tam m isto found that 
antagonism  of opioids w ith naloxone after balanced anaesthesia at 
norm otherm ia causes marked increases in system ic oxygen uptake 97. However, 
their findings could be explained by increased muscular work as a result of 
restlessness and shivering whereas in the present study the patients w ere  given 
suffic ient atracurium to  produce complete neuromuscular blockade. Malin and 
colleagues found that chronic, but not acute, exposure of conscious rats to  
naloxone resulted in an abstinence-like state and a marked increase in system ic 
oxygen uptake 98. In the present study, only a single bolus dose of naloxone 
was given whereas, in Malin and colleagues study, it took a continuous infusion 
of na loxone over 24 hours to produce an increase in system ic oxygen uptake.
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Also, Malin and colleagues could not reproduce the response w ith  bolus doses 
of naloxone. In contrast, Dick, Lotz and Traub 163 found that naloxone 0.4 mg IV 
given to  op io id  naive volunteers caused a small but significant decrease in 
system ic oxygen uptake. The present study’s findings w ould  suggest that 
alfentanil and its antagonism with naloxone have no im portant e ffect on 
system ic oxygen uptake in humans during hypothermic cardiopulmonary bypass.
Com parison of lactate concentrations in Period 1 betw een Groups I and II 
found no significant difference which would suggest that alfentanil does not 
influence anaerobic metabolism. Although nonsignificant, small decreases in 
lactate concentration occurred between Periods 1 and 2 in both groups. This is 
in agreem ent w ith  previous findings as lactate concentration w ou ld  be expected 
to  decrease slightly over the course of cardiopulmonary bypass.
Haemodynamics
Comparison of haemodynamic variables in Period 1 show ed no significant 
difference between the groups. This finding would imply that alfentanil has little 
or no e ffect on haemodynamic variables during this stage of cardiopulmonary 
bypass. However, within patient comparison of mean arterial pressure from 
Periods 1 to  2 found a difference in effect between the Groups. In Group I, there 
was little  if any change in mean arterial pressure or peripheral vascular 
resistance from  the control measurements in Period 1 to  those after alfentanil 
was adm inistered in Period 2. Yet during the course of cardiopulm onary bypass, 
a progressive increase in both of these variables w ould be expected. This 
consistency in mean arterial pressure and peripheral vascular resistance 
throughout the test periods might suggest that alfentanil am eliorated the 
ongoing vasoconstriction. Indeed, the findings from Group II w ou ld  add weight 
to  this supposition as reversing alfentanil w ith naloxone produced a 30% 
average increase in mean arterial pressure and peripheral vascular resistance 
from Periods 1 to  2. This is a greater increase than w ould be expected, given 
the findings in Chapter 5, as solely attributable to  ongoing vasoconstriction.
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Antagonism of opioids w ith naloxone results in abrupt increases in 
system ic arterial pressure and peripheral vascular resistance in the intact 
cardiovascular system at normothermia 164. These increases are most likely 
m ediated by catecholam ines and are ascribed to  sudden awakening and 
reversal of analgesia. Naloxone has been reported to  reverse hypotension in 
som e specific situations such as endotoxic shock and high cervical spine injury 
165,166 por ^ is  reason, the rise in mean arterial and peripheral vascular resistance 
in the present study could be, in theory, due to  the direct action of naloxone. 
However, naloxone has not been shown to  have any cardiovascular effects in 
humans during halothane anaesthesia 167. Thus, it is likely that the vascular 
effects in the present study are due to  antagonism of alfentanil rather than as a 
direct action of naloxone.
In an anaesthetised canine model w ith an intact cardiovascular system, 
Flacke and co-w orkers found that antagonism of fentanyl w ith naloxone 
produced marked increases in catecholam ines, mean arterial pressure and 
peripheral vascular resistance 16^  They postulated that the haemodynamic 
effects were as a result of an increase in sym pathetic tone mediated by the 
central nervous system. It is likely that the increases in mean arterial pressure 
and peripheral vascular resistance produced by antagonism of alfentanil in this 
study is a result of the same mechanism. These findings would suggest that 
opioids have an important role in the prevention of the progressive 
vasoconstriction that occurs during cardiopulmonary bypass.
Isoflurane concentration
Marked interpatient variation in blood isoflurane concentrations were again 
found in this study. Mean isoflurane concentration was about 50% higher in 
Group I than Group II during both Periods though this difference was not 
statistically significant. The likely explanation for this chance difference is a 
higher gas to  blood ratio in the oxygenator in Group I a llow ing greater delivery 
of isoflurane. The higher arterial oxygen tension in Group I would support this
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conclusion. Isoflurane concentration could then account for the slightly lower 
mean arterial pressure and peripheral vascular resistance in Group I during 
Period 1 and in part for the between group differences in Period 2. However, 
there were only small nonsignificant changes in isoflurane concentration 
between Periods 1 and 2 in both groups therefore any w ithin group changes in 
mean arterial pressure and peripheral vascular resistance over this tim e is 
unlikely to be caused by isoflurane.
In conclusion, neither the adm inistration of alfentanil nor antagonism of 
alfentanil w ith naloxone had any significant effect on system ic oxygen uptake. 
In contrast, expected increases in mean arterial pressure and peripheral vascular 
resistance did not occur after alfentanil was given, but marked increases 
occurred when alfentanil was antagonised w ith naloxone. These haemodynam ic 
findings would suggest that alfentanil is an important moderator of the 
progressive vasoconstriction associated w ith cardiopulmonary bypass.
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CONCLUDING DISCUSSION
This chapter w ill draw overall conclusions, based on the presented studies 
and w ith reference to  previous literature, as to  the effects of cardiopulmonary 
bypass and anaesthesia on haemodynamic and m etabolic variables. Areas 
requiring further research w ill be identified. Finally, the place of cardiopulmonary 
bypass as a haemodynamic model and the function of anaesthesia during 
cardiopulmonary bypass w ill be considered.
From the foregoing studies, it is clear that the m ost important factor in 
term s of systemic metabolism is flo w  rate. Anaesthesia, acid-base 
m anagement and flow  character during hypotherm ic cardiopulmonary bypass 
had little if any metabolic actions. With reference to haemodynamic variables, 
these were markedly affected by some of the anaesthetic agents which were 
tested as well as by flow  rate and acid-base m anagement but they were not 
influenced by flow  character.
METHODOLOGY
The greatest difficulty in comparing previous work is the tremendous 
variety and combination of anaesthetic and cardiopulmonary bypass techniques 
which have been used. An excellent exam ple of this problem is the controversy, 
despite extensive investigation, that still surrounds pulsatile perfusion 12. Care 
w as taken in this series of studies to  standardise, w ith the exception of the 
variable under study, both anaesthetic and cardiopulmonary bypass techniques. 
As previously discussed, using a factorial experim ental design for the studies in 
Chapter 5 largely overcom es most of the difficulties in standardisation. With
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regard to  anaesthesia, although tw o  opioids and neuromuscular blocking agents 
were used in this series of studies, the known effects of these agents are 
readily com parable 9 3 ,9 4 , 9 5  Thus, it is possible to  make a valid over all 
comparison from  these studies.
Ideally, no vasoactive drugs would have been used during these studies 
other than those which were under investigation. However, for the reasons 
discussed in Chapter 2, it would be ethically unsound to  a llow  patients to  suffer 
unacceptably low  or high levels of systemic arterial pressure. Because of this, 
the changes which w ere found w ith regard to  haemodynamic variables may be 
less than precise. An animal model might have a llowed greater trespass but 
whether animal findings can be extrapolated to  humans must always be 
questionable. Although the present series of studies in humans may have 
underestimated the magnitude of any effects, they would have accurately 
reflected their directions. It m ight also be argued that the vasoactive drugs used 
to control hypertension and hypotension may have influenced m etabolism . 
However, sodium nitroprusside has been shown to have no effect on system ic 
oxygen uptake during cardiopulmonary bypass 46 and m ethoxam ine, being a 
pure alpha-adrenergic agonist, has no metabolic actions.
Patient m edication w ith  beta-adrenergic and calcium channel blocking 
agents are known to  m odify the haemodynamic responses to vasoactive agents 
during cardiopulmonary bypass 120. Any effects these agents might have had w ill 
have been contro lled in the crossover studies of Chapters 5 and 6. In the parallel 
group studies of Chapters 7 and 8 there was a similar distribution of these 
agents in both the control and active groups. It is therefore unlikely that 
pre-operative m edication w ith  beta adrenergic or calcium channel blockers w ill 
have in any way invalidated the findings of this thesis.
100
Chapter 9 Concluding Discussion
EFFECTS OF CARDIOPULMONARY BYPASS ON METABOLISM
Of the three aspects of cardiopulmonary bypass studied, that is flow  rate, 
flow  character and acid-base management, only flow  rate had a significant 
e ffect on metabolism. Pump flow  rate is frequently decreased to  low  levels 
during hypothermia on the basis that this manipulation improves myocardial 
preservation, reduces haemolysis and gaseous m icroem bolisation and provides 
a clearer surgical field 22,54,62 j h e findings of this project would suggest that the 
physiological rationale for this manipulation is flawed and that system ic oxygen 
uptake was markedly reduced when flow  rate was decreased from 2.0 to  1.5 
L.m in-1.m-2. Interpretation of this finding in term s of clinical outcom e is difficult 
as low flow  cardiopulmonary bypass is w ell tolerated 10'168. Undoubtedly many 
tissues can w ithstand hypoperfusion in the presence of hypotherm ia for long 
periods of tim e w ithout structural damage and cerebral perfusion may be 
preferentially preserved 169. Physiologically, and as others have proposed 170,171 
it should be better to  ensure that the system ic oxygen uptake is on the plateau 
rather than the upslope of the curve. However, the question remains whether, 
w ith  modern cardioplegic techniques, the use of low flow  cardiopulmonary 
bypass to  enhance myocardial preservation can still be justified. Determ ination 
of the flow  rate at which system ic oxygen uptake becomes unrelated requires 
further investigation under the current conditions of cardiopulmonary bypass.
Flow character
Unfortunately, the findings of the experiments in Chapter 5 do not 
conclusively resolve the long established controversy that continues to  surround 
the use of nonpulsatile versus pulsatile perfusion 12,23,65,66 Pulsatile flow  has 
been advocated on the basis that it im proves metabolism 65, yet no significant 
differences between pulsatile and nonpulsatile flow  characters w ere found in 
these studies. These findings cannot com plete ly exclude the theory that 
pulsatile flow  is metabolically superior to  nonpulsatile perfusion, but they would
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add w e igh t to  the body of opinion which maintains that there are no im portant 
m etabolic differences between the tw o  types of flow  character during routine 
cardiopulmonary bypass 2266.
In this area of research, there remains a great deal of confusion as to  what 
constitutes truly pulsatile perfusion 12. Recent studies by several groups 15°- 
152 155, which have identified the com plex nature of pulsatile perfusion, may heip 
resolve this important question. The modified roller pump system used in the 
present study may account for pulsatile perfusion’s lack of e ffect on 
haemodynam ic and m etabolic variables as it produces only lim ited pulsatile 
power 150,151 However, the same pulsatile system was used previously in a 
series of studies by Taylor which found significant haemodynamic and hormonal 
differences between nonpulsatile and pulsatile perfusion 172. These findings are 
difficult to  resolve although Taylor employed normotherm ia as opposed to  the 
hypotherm ia used in the present studies. A lso, p lebo tom y prior to  
cardiopulmonary bypass for later autologous transfusion was routinely practised 
at that tim e in the centre in which Taylor undertook his studies. This p lebotom y 
may have caused an abnormally high state of vasoconstriction which, in turn, 
may have resulted in an altered response to flow  character.
Further study is required to determ ine if there are truly advantages during 
clinical cardiopulmonary bypass to  the use of pulsatile over nonpulsatile 
perfusion. A clearly agreed definition of what constitutes pulsatile and 
nonpulsatile perfusion is required, as well as the use of an accurate 
measurement of pulsatility, before this controversy can be resolved.
Acid-base management
Acid-base m anagement during hypothermic cardiopulmonary bypass has 
attracted a lot of attention since Rahn and Reeves and Howell and colleagues 
put forw ard their arguments, based on comparative physiology, for using an 
a lpha-stat rather than a pH -stat acid-base management during hypotherm ia 
7 7 - 7 9  findings of the experiment in Chapter 5 add no weight to the use of 
either type of acid-base management in term s of system ic m etabolism .
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However, em ploym ent of alpha-stat control would appear to  have favourable 
regional effects on cerebral and myocardial metabolism 173.174
Anaerobic metabolism
Lactate concentration and base excess proved to  be poor indices of 
metabolism during hypotherm ic cardiopulmonary bypass in this series of studies. 
Even when marked changes in system ic oxygen uptake occurred, such as 
produced by alternation in flow  rate, there were no significant changes in either 
lactate concentration or base excess. The only consistent pattern throughout the 
studies, although not always statistically significant, was a small mean reduction 
in lactate concentration during the course of cardiopulmonary bypass. This is in 
contrast to  earlier studies which observed progressive increases in lactate 
concentration 5 48. M etabolism  or the redistribution of lactate present in the 
pump prim ing solution may account for the present results. The im plication of 
this finding is that cardiopulmonary bypass today causes less physiological 
trespass than it has done in the past.
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EFFECTS OF ANAESTHESIA DURING CARDIOPULMONARY BYPASS
ON METABOLISM
None of the anaesthetic agents examined in the preceding studies were 
found to  have any significant effect on metabolism  during hypotnerm ic 
cardiopulmonary bypass. This was an unexpected finding given previous 
research which has found anaesthetic agents to  reduce system ic oxygen uptake 
both in the intact cardiovascular system and during cardiopulmonary bypass 
85,87,90-92 Several possible explanations for the differences betw een present and 
previous findings can be mooted. As discussed in Chapter 7 , atracurium’s 
m inimal haemodynam ic effects, unlike tubocurarine’s potent vasodilatory 
actions, may account for the lack of any m etabolic e ffect in the present studies. 
Vasodilation alone seems an unlikely explanation as this was produced by 
isoflurane in the study documented in Chapter 6  and also, by Evans and 
co -w orkers 46 using sodium nitroprusside w ithout concom itant m etabolic 
changes.
Theye and M ichenfelder have argued that in the intact cardiovascular 
system, the decrease in systemic oxygen uptake induced by anaesthetic agents 
may be m ediated through a decrease in cardiac output rather than system ic 
m etabolic depression 91. As pump flow  rate was kept constant during the 
present studies of anaesthetic agents, this effect would not occur. However, this 
is unlikely to  be the whole explanation as anaesthesia has regional m etabolic 
e ffects during cardiopulmonary bypass which cannot be ascribed to  flow  rate 161.
Another im portant difference from early studies is the current use of 
hypotherm ia in conjunction w ith cardiopulmonary bypass. M oderate hypotherm ia 
causes approxim ate ly a 50% reduction in m etabolic rate 22 and therefore, it may 
be that the size of any systemic metabolic effect induced by anaesthetic agents 
is very small at hypothermia in comparison to  norm otherm ia. Thus, the 
m easurem ent techniques used in the present studies may not have been
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sensitive enough to  detect any changes. If the m etabolic e ffects of anaesthesia 
are indeed so small during hypothermia, it is unlikely that they are of any clinical 
relevance. However, the present studies cannot exclude the possib ility that 
anaesthesia has im portant system ic metabolic effects during coo ling and, in 
particular, the rewarm ing stages of hypothermic cardiopulmonary bypass. 
Moreover, future anaesthetic drugs may prove to  have system ic m etabolic 
actions.
One im portant group of drugs which were not exam ined in this thesis, 
because of their large number and disparate nature, are the intravenous 
anaesthetics. Chlorprom azine has been found by Arikawa and colleagues to 
increase system ic oxygen uptake below 32°C " .  However, its use is not 
presently favoured for cardiopulmonary bypass 20. Many of the other intravenous 
agents used could potentia lly be systemic metabolic depressants as m ost are 
known to  decrease regional metabolism. Propofol is a new agent which is 
w orthy of further study because of its increasing use during cardiopulm onary 
bypass 20.
The regional m etabolic effects of anaesthesia during cardiopulm onary 
bypass, and in particular the effects on cerebral m etabolism , require 
investigation. There is an important neuropsychological m orbidity fo llow ing  
cardiopulmonary bypass 175176 and thiopentone is the only agent that has been 
dem onstrated to  reduce this morbidity 177. Most likely this e ffect is m ediated by 
th iopen tone ’s cerebral depressant action 161. However, in the doses of 
th iopentone that are required for cerebral protection, there is an increased need 
for ionotropes and prolonged ventilatory support 177. Other anaesthetic agents 
such as isoflurane or propofol, which also depress cerebral m etabolic rate 161, 
may prove to  be cerebrally protective if adm inistered during cardiopulm onary 
bypass w ithout the adverse cardiovascular and ventilatory e ffects  of 
th iopentone. This aspect of anaesthesia during cardiopulmonary bypass requires 
thorough investigation.
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EFFECTS OF CARDIOPULMONARY BYPASS ON HAEMODYNAMICS
Of the three technical aspects of cardiopulmonary bypass exam ined in the 
present series of studies, only flow  rate had a significant and sizeable e ffect on 
haem odynam ic variables. Although arterial pH was found to  interact significantly 
w ith  stage on mean arterial pressure, the magnitude of this e ffect was small. No 
differences in haemodynamic variables were found between nonpulsatile and 
pulsatile perfusion. Regardless of flow  rate, flow  character and acid-base 
m anagem ent, there was a progressive increase in both mean arterial pressure 
and peripheral vascular resistance throughout the course of cardiopulmonary 
bypass.
Flow rate
The increase in peripheral vascular resistance associated w ith  decreasing 
flow  rate, which was found in the present study, confirm s that the inverse 
relationship betw een these tw o variables still exists despite the m ajor changes 
in cardiopulm onary bypass that have occurred over the years34 123. Of interest, 
and not previously described, is the significant correlation betw een the changes 
in peripheral vascular resistance and systemic oxygen uptake which resulted 
from  alternation of the flow  rate. This proportional relationship im plies that the 
more peripheral vascular resistance is reduced by increasing flo w  rate, then the 
greater is the im provem ent in tissue perfusion.
In contrast, the progressive increase in peripheral vascular resistance over 
the course of cardiopulmonary bypass was not associated w ith  any decrease in 
system ic oxygen uptake. As discussed in Chapter 5, these conflic ting  results 
may indicate that both passive and active capillary mechanisms are operating to 
cause the increases in peripheral vascular resistance.
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Flow character
Pulsatile perfusion is stated to be haemodynam ically superior to 
continuous perfusion as it reduces peripheral vascular resistance as well as 
preventing ineluctable vasoconstriction. The results of this project do not 
support this view  as there were no significant d ifferences in haemodynamic 
variables between nonpulsatile and pulsatile perfusion nor any significant 
d ifference in the rate at which these variables increased during cardiopulmonary 
bypass. As discussed previously, there may be technical explanations as to why 
the m odified roller pump system used in this thesis did not produce truly 
pulsatile perfusion. Nonetheless, the findings of the present studies would 
support the view  that there are no important haem odynam ic differences
b e tw e en  nonpulsatile  and pulsatile perfusion even during low  flow
cardiopulmonary bypass 2266.
Acid-base management
Som e differences in haemodynamic effects betw een alpha and pH-stat 
ac id -base management were found in the present studies but the clinical 
consequences of these differences is uncertain. There is a grow ing body of 
research which would indicate that alpha-stat acid-base m anagement may be 
advantageous as it maintains cerebral blood flow  autoregulation and gives 
im proved myocardial preservation 173.174 until o therw ise determined, an 
a lpha-sta t approach would, therefore, appear the m ore appropriate choice of 
ac id -base management during hypothermic cardiopulm onary bypass. However,
this series of studies demonstrates that achieving alpha-stat acid-base
m anagem ent is not staightforward when using bubble oxygenators.
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EFFECTS OF ANAESTHESIA DURING CARDIOPULMONARY BYPASS
ON HAEMODYNAMICS
The second hypothesis of this project was that anaesthesia had im portant 
e ffects on haemodynam ic variables. Of the three main com ponents of balanced 
anaesthesia which w ere studied, this hypothesis was supported w ith  regard to  
the inhalational and opio id anaesthetic agents but this was not the case w ith  the 
neuromuscular blocking agent.
Inhalational anaesthetics
Isoflurane was found to  be a vasodilator during the abnormal conditions of 
hypotherm ic cardiopulmonary bypass as is the case in the intact cardiovascular 
system at normotherm ia. Given that awareness is a recognised com plication 
during cardiopulmonary bypass i 79.i8o> the use of isoflurane to  control 
hypertension during cardiopulmonary bypass, as opposed to  non-anaesthetic 
vasodilators, would have im portant advantages as it would at least lessen, and 
at best obviate, the risk of awareness. It would seem most appropriate to  use 
isoflurane during rewarm ing when the flow  rate is increased and the ongoing 
vasoconstriction reveals itself as hypertension.
Nevertheless, there may be drawbacks to the use of isoflurane in high 
concentrations throughout cardiopulmonary bypass. Once hypotherm ia has been 
achieved, the flow  rate is often reduced to  low levels. This reduction in flo w  
rate, com bined w ith a low  peripheral vascular resistance, can result in 
hypotension at this stage. Using high concentration of isoflurane at an early 
stage during cardiopulmonary bypass may exacerbate this problem  and result in 
unacceptably low  system ic arterial pressures. However, awareness is unlikely to 
occur at this stage of cardiopulmonary bypass because of the hypotherm ia and, 
therefore, isoflurane could be used in low concentrations at this tim e. 
A lternatively, short acting vasoconstrictors could be adm inistered to  maintain
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the arterial pressure at acceptable levels. Another drawback to using high 
concentrations of isoflurane throughout cardiopulmonary bypass may be it’s 
effects when weaning back to  the patient’s ow n cardiovascular system. At this 
crucial time, high concentrations of isoflurane may impair myocardial 
perform ance and this may already be depressed as a result of cross clamping 
ischaemia. For that reason, low  concentrations of isoflurane may be advisable at 
this point. However, this is readily achieved as it takes only 1 0  minutes for the 
blood isoflurane concentration to drop to  low  levels after discontinuing 
adm inistration during cardiopulmonary bypass 180.
As discussed earlier, cerebral protection may be another reason for using 
isoflurane during cardiopulmonary bypass. Suppression of the stress response to 
cardiopulmonary bypass may yet prove to be a further indication for the use of 
isoflurane 18181.
Although there may be drawbacks to  the use of isoflurane during 
cardiopulmonary bypass, these can be readily overcom e and this study would 
suggest that any disadvantages are greatly ou t-w e ighed by the advantages.
Neuromuscular blocking agents.
In recent years, there has been a move towards the use of neuromuscular 
blocking agents, such as atracurium and vecuronium, which, unlike the 
established agents, have minimal effects on the cardiovascular system. This is 
particularly true in anaesthesia for coronary artery surgery when stable 
haemodynamics and avoidance of tachycardia are im portant in order to prevent 
myocardial ischaemia. The present study found atracurium to  have no significant 
e ffect on haemodynamic variables during cardiopulmonary bypass, which fits 
w ith  previous studies in the intact cardiovascular system  at normotherm ia 131.132 
Atracurium, because of its minimal cardiovascular effects, before, during and 
after cardiopulmonary bypass, would appear to  be a suitable agent for 
neuromuscular blockade during cardiac surgery.
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Whether any neuromuscular blocking agent is in fact required, given the 
risk of patient awareness during cardiopulmonary bypass 178,179 jS m 0re 
questionable. Depth of anaesthesia is a lm ost impossible to determ ine during 
cardiopulmonary bypass as all the major clinical signs are ablated. One of the 
perceived truths regarding depth of anaesthesia is that movem ent in response 
to a painful stimulus indicates a level of consciousness which is close to 
awareness and signifies that anaesthesia should be deepened. This vital sign is 
lost when movem ent is inhibited by neuromuscular blocking agents. During 
cardiac surgery, muscle relaxation is not required, even during sternotom y, for 
surgical access. If neuromuscular blockers w ere  not used then unduly light 
anaesthesia would become readily apparent and could be quickly remedied 96. In 
contrast, preventing movem ent w ith neuromuscular blocking agents may 
disguise awareness 179 and result in serious psychological trauma to the patient, 
which may lead to litigation.
Opioids
Alfentanil’s actions on the vascular system  in the present studies were 
unexpected as it has minimal effects on haemodynamic variables in the intact 
cardiovascular system  at norm otherm ia  95,134 indeed com parison of 
haemodynamic variables between groups in Period 1 w ithout consideration of 
the results from Period 2  would support these findings. However, when the 
findings during Period 2 are included, they would suggest that alfentanil may 
reduce the rate of progressive vasoconstriction that occurs during the course of 
cardiopulmonary bypass. It is unlikely that opioids prevent the progressive 
vasoconstriction altogether, as in Chapter 5 a significant rise in peripheral 
vascular resistance was found during the course of cardiopulmonary bypass. In 
tha t expe rim e n t, pa tien ts  w e re  a n a e s th e tise d  during hypo the rm ic  
cardiopulmonary bypass w ith an infusion of fentanyl which is a similar opio id to  
alfentanil 95. Therefore, it is more likely that opioids reduce the rate at which 
peripheral vascular resistance rises. The use of opioids like alfentanil during
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cardiopulmonary bypass would seem to  be beneficial in m inimising the adverse 
increase in peripheral vasoconstriction that originates during cardiopulmonary 
bypass and continues into the postoperative period.
Another advantage to the use of opio ids during cardiopulmonary bypass is 
that, if used in high doses, they block the stress response 95. However, w ithout 
supplem entation by an inhalational or intravenous anaesthetic, there is a risk of 
awareness w ith  opioid techniques 95 96 .
Intravenous anaesthetics
Only three drugs, chosen as representative of the three main com ponents 
of balanced anaesthesia, were investigated in the foregoing studies. One group 
of drugs not investigated in this project, because of its large size and disparate 
nature, were the intravenous anaesthetic agents. These agents include 
barbiturates, benzodiazepines, neurolepts and other non-re lated drugs like 
propofol and are som etim es used alone or, more com m only, in conjunction w ith 
opioids during cardiopulmonary bypass 20. Most of these agents have been 
found to  cause decreases in peripheral vascular resistance during 
cardiopulmonary bypass 1 1 7 , 1 2 1 , 1 3 5 - 1 3 7
Barbiturates, like thiopentone and m ethohexitone, are now less frequently 
used than in the past. This decreased use is perhaps because of their long 
elim ination half life and the profound cardiovascular depression which they 
produce, as this is disadvantageous during the post-bypass period. However, 
the use of thiopentone in high doses has recently been advocated, despite its 
adverse side effects, on the basis that it provides cerebral protection during 
cardiopulmonary bypass 178. Benzodiazepines, like midazolam and diazepam, 
are frequently used during cardiopulmonary bypass. These agents also have a 
long half life though, unlike the barbiturates, they are noted for their minimal 
haemodynam ic effects in the intact cardiovascular system. Neurolept 
anaesthetic agents such as chlorpromazine and droperidol, are known to  be 
vasodilators during cardiopulmonary bypass and are used for this effect 99117.
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Recently, their use during cardiac anaesthesia has declined 20. Why this should 
be is uncertain though perhaps the decline in the popularity of neurolepts can be 
ascribed to  their prolonged action.
Propofol is a new, short acting intravenous anaesthetic agent which has 
becom e com m ercia lly available since these studies w e re  undertaken. During 
hypotherm ic cardiopulmonary bypass, propofol is a vasodilator 135,136 Therefore, 
propofol could be a suitable alternative to  isoflurane as an anaesthetic agent to 
control system ic arterial pressure and ensure anaesthesia w ithout the risk of 
awareness.
HAEMODYNAMIC MODEL
Cardiopulm onary bypass has been advocated by Levy and Hug as a 
suitable experim ental model for study of the circulation 100 and others have used 
it as such 117-120129 jh e  findings of the foregoing studies indicate the difficulties 
involved in interpreting complex haemodynamic changes that occur during 
hypotherm ic cardiopulmonary bypass. Not only are there m ultiple factors, which 
influence haemodynam ic variables during cardiopulmonary bypass, but these 
influences are dynamic so a steady state is never achieved. Throughout 
cardiopulmonary bypass, there is a progressive arterial vasoconstriction. 
M oreover, there is an altered response of the vasculature depending on the 
stage of cardiopulmonary bypass. This is dem onstrated by the interaction 
betw een arterial pH and stage in Chapter 5 and also by the altered responses to 
isoflurane and alfentanil in Chapters 6 and 8 according to  the stage of 
cardiopulm onary bypass in which they were adm inistered. Although study of 
these influences are important for their own sake, it is doubtful whether findings 
made during the abnormal conditions of hypotherm ic cardiopulmonary bypass 
can be extrapolated directly to the intact cardiovascular at normotherm ia.
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ANAESTHESIA DURING CARDIOPULMONARY BYPASS
After ensuring the patients safety, the prime duty anaesthetists owe their 
patients is to render them insensible to surgery. This duty can be difficult to fulfil 
during cardiac anaesthesia when occasionally a life threatening cardiovascular 
collapse may necessitate the lightening of anaesthesia to  elim inate any adverse 
cardiovascular effects of anaesthesia. Also, during cardiopulmonary bypass the 
clinical signs indicating depth of anaesthesia, such as heart rate and arterial 
b lood pressure, are rendered useless by the induced haemodynamic 
derangem ent. There may be m itigating circumstances for patient awareness 
before  and after cardiopulmonary bypass but not during, when the circulation is 
mechanically supported. A very small m inority of anaesthetists do not administer 
any form  of anaesthesia during cardiopulmonary bypass 20 w ith the result that 
som e patients can clearly recall in tra-operative events 179. Although the type of 
anaesthetic technique that should be used can be argued, there can be no 
acceptable reason for not administering som e form  of anaesthesia during 
cardiopulmonary bypass.
In conclusion, this thesis has proven the hypothesis that cardiopulmonary 
bypass technique has an important influence, in term s of flow  rate, on 
haem odynam ic and metabolic variables to  be valid. With regards to  the 
hypothesis that anaesthesia has important m etabolic and haemodynamic effects 
during hypothermic cardiopulmonary bypass, it can be accepted for 
haem odynam ic effects but must be rejected in the case of m etabolic effects.
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GLOSSARY OF ABREVIATIONS
BE base excess
C a 0 2 arterial blood oxygen content
C v 0 2 venous blood oxygen content
C a -v 0 2 oxygen extraction
CVP central venous pressure
d mean difference
d 95% confidence lim its of mean difference
DAP diastolic arterial pressure
d o 2 system ic oxygen delivery
F F-statistic or fem ale
GLIM generalised linear interactive m odelling
Hba arterial haemoglobin concentration
Hbv venous haemoglobin concentration
kg kilogram
L litre
m metre
m2 square m etre
min minute
M male
MAP mean arterial pressure
P probability
P a 0 2 arterial blood oxygen tension
P a C 02 arterial blood carbon dioxide tension
P v 0 2 m ixed venous blood oxygen tension
P vC 02 mixed venous blood carbon dioxide tension
pHa arterial pH
pHA pH -sta t acid-base management
P^37 alpha-stat acid-base management
PVR peripheral vascular resistance
126
r regression coefic ient
S a 0 2 arterial haemoglobin oxygen saturation
S v 0 2 mixed venous haemoglobin oxygen saturation
SAP systolic arterial pressure
SD standard deviation
<N
O•>
systemic oxygen uptake
yr year
95% CL 95% confidence lim it
A change
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